Dissertations / Theses on the topic 'Cardiovascular diseases; Heart; Cardiac'

Heart failure resulting from different forms of cardiomyopathy is defined as the inability of the heart to pump sufficient blood to meet the body's metabolic demands. It is a major disease burden worldwide and the statistics show that 50% of the people who have the heart failure will eventually die from sudden cardiac death (SCD) associated with an arrhythmia. The central cause of disability and SCD is because of ventricular arrhythmias. Genetic mutations and acquired modifications to RyR2, the calcium release channel from sarcoplasmic reticulum, can increase the pathologic SR Ca2+ leak during diastole, which leads to defects in SR calcium handling and causes ventricular arrhythmias. The mechanism of RyR2 dysfunction includes abnormal phosphorylation, disrupted interaction with regulatory proteins and ions, or altered RyR2 domain interactions. Many pharmacological strategies have shown promising prospects to modulate the RyR2 as a therapy for treating cardiac arrhythmias. Here, we are trying to establish a novel approach to designing new drugs to treat heart failure and cardiac arrhythmias. Previously, we demonstrated that all pharmacological inhibitors of RyR channels are electron donors while all activators of RyR channels are electron acceptors. This was the first demonstration that an exchange of electrons was a common molecular mechanism involved in modifying the function of the RyR. Moreover, we found that there is a strong correlation between the strength of the electron donor/acceptor, and its potency as a channel inhibitor/activator, which could serve as a basis and direction for developing new drugs targeting the RyR. In this study, two new potent RyR inhibitors, 4-methoxy-3-methyl phenol (4-MmC) and the 1,3 dioxole derivative of K201, were synthesized which are derivatives of the known RyR modulators, 4-chloro-3-methyl phenol (4-CmC) and K201. The ability of K201, 1,3 dioxole derivative of K201 and 4-MmC to inhibit the cardiac calcium channel is examined and compared at the single channel level. All of these compounds inhibited the channel activity at low micromolar concentrations or sub-micromolar concentrations.

Cardiovascular disease is a leading cause of death worldwide and becomes increasingly prevalent in the elderly population. Independent of etiopathogenesis, heart failure (HF) is the final common stage of numerous heart diseases. Cardiac stem cell (CSC) therapy has emerged as a promising cell-based strategy for treatment of HF. However, cell replacement is not able to fully restore a structurally damaged myocardium in advanced and end-stage HF. The objective of this project was to test the following hypotheses: that a bioengineered heart extracellular matrix (ECM) with preserved intact geometric structure could be generated using decellularization by coronary perfusion; and that autologous CSCs, to repopulate this ECM, could be isolated and expanded from the adult heart, with the caveat that autologous CSCs are depleted and impaired by both aging and chronic dilated cardiomyopathy. This will help to develop a possible therapeutic approach for advanced HF, using a combination of CSCs and engineering technique. Resident CSCs were isolated from explant-derived cells (EDCs) and expanded into cardiosphere-derived cells (CDCs) via cardiosphere formation. The CDCs expressed CSC markers (c-kit and Sca-1), pluripotent markers (Oct3/4 and Sox2), and the cardiac lineage-committed marker (Nkx2.5), and showed clonal expansion, self-renewal, and cardiomyogenic potential in vitro. In tissue engineering experiments, CDCs survived and proliferated within biomaterial alginate scaffolds for up to 7 weeks. An engineered bioartificial ECM scaffold was successfully produced from a whole rat heart using retrograde coronary perfusion and possessed an intact 3D architecture with functionally perfusable vascular network. Compared with ventricles, cultures derived from atria produced significantly higher number of c-kit+ and Sca-1+ CSCs (c-kit: 13% vs. 3.4%; Sca-1: 82% vs. 53%, respectively) and exhibited greater clonogenic and proliferative capacity. CDCs could be grown from young and aged mice, but the yield of CSCs significantly declined with age, as did cell migration and differentiation potential. In comparison to wild-type mice, atrial-CDCs from dystrophic mice showed no significant differences in CSC subpopulations and characteristics, despite confirmation of cardiac dysfunction using MRI. In conclusion, CDCs could be considered to be a viable cell candidate for cardiac therapy and may be used to treat HF at various stages, in combination with myocardial tissue engineering.

Congenital heart disease is the most common congenital anomaly, affecting approximately 1% of all live births each year. Although clinical interventions are improving, many affected infants do not survive to adulthood. Congenital cardiac defects originate from disturbances during development, making the study of mammalian cardiogenesis critical to improving outcomes for infants with congenital heart disease. Development of the mammalian heart involves epigenetically-driven specification and commitment of a diverse landscape of cardiac progenitors. Recent studies determined that chromatin modifying enzymes play a previously underappreciated role in the pathogenesis of congenital heart defects. This thesis investigates the functions of Hdac1 and Hdac2, highly homologous Class I histone deacetylases, during early murine cardiac development. We establish that Hdac1 and Hdac2 cooperatively regulate cardiogenesis in distinct cardiac progenitor populations during development. Together, our findings demonstrate that Hdac1 and Hdac2 are critical mediators of the earliest stages of mammalian cardiogenesis through a variety of spatiotemporally specific, redundant, and dose-sensitive roles and indicate they may play important roles in the pathogenesis of human congenital cardiac defects.

Abstract It has widely been shown that exercise, particularly aerobic exercise, has extensive cardioprotective benefits and is an important tool in the prevention of coronary heart disease (CHD). The present investigation aimed to determine the multivariate impact of strength training, designed to prevent the development of CHD, on the Framingham Risk Assessment (FRA) score. Twenty-eight healthy untrained men with low CHD risk (mean age 28 years and 7 months) participated in an eight-week (3- d/wk) strength training programme. Self-administered smoking records, resting blood pressures, total cholesterol (TC), high-density lipoprotein cholesterol (HDLC), FRA scores and absolute 10-year risks for CHD were determined at the pre-test and post-test. After the eight-week period, no significant (p > 0.05) differences were found in number of cigarettes smoked daily, systolic blood pressure, TC, HDLC, FRA scores and absolute 10-year risks for CHD in both the strength-trained (n = 13) and non-exercising control (n = 15) groups. The data indicate that strength training did not reduce the risk of developing CHD and absolute 10-year risk for CHD as assessed by the FRA score.

Cardiovascular pathology is seen in both animals and humans after domoic acid intoxication. Whether this damage is direct (i.e., cardiotoxic) or indirect (i.e., CNS/autonomic seizures) is not known. We have previously shown that acute in vitro domoic acid (0.05-0.25[mu]M; 10 min) treatment of isolated cardiac mitochondria compromises mitochondrial FADH and NAD⁺-linked respiratory control and mitochondrial energetics. Domoic acid was shown to traverse and bind the cellular membrane of H9c2 cardiac myoblasts. However it did not compromise cellular viability as assessed using cell quantification or lactate dehydrogenase leakage assays. Exposure of intact H9c2 cells to domoic acid only resulted in complex II-III activity impairment and assessment of reactive oxygen species (superoxide and hydrogen peroxide) production in both isolated cardiac mitochondria and H9c2 cardiomyocytes failed to show any significant differences following exposure to domoic acid. Acute ex vivo domoic acid treatment of an isolated myocardium in Langendorff perfusion mode failed to result in cardiac haemodynamic dysfunction, however there appeared to be small but significant decrease in mitochondrial oxygen utilization. The absence of any substantial damage to intact cardiomyocytes and isolated myocardium suggested that domoic acid does not have a direct toxicological effect on cardiac energetics. We therefore investigated the possibility that cardiovascular pathology is an indirect consequence of autonomic seizure activity. Domoic acid was administered intraperitoneally or intrahippocampally and the development of cardiac pathologies was assessed and compared. Sprague-Dawley rats receiving either i.p. or i.h. domoic acid were assessed behaviourally and shown to reach similar levels in their cumulative seizure scores. Assessment of the cardiac haemodynamics (LVDP, dP/dt, heart rate and coronary flow) revealed a significant time-dependent decrease in function at 1, 3, 7 & 14-days post-i.p. and 7 & 14-days post-i.h. domoic acid administration. Measurement of ventricular mitochondrial oxygen utilization revealed a similar time-dependent decrease in respiratory control, which appeared to be associated with increased proton leakage, shown by an increase in state-4 respiration rate (P<0.01). Assessment of the mitochondrial electron transport chain (complexes I-V) and the mitochondrial marker of integrity, citrate synthase, showed marked time-dependent impairment in both models of domoic acid -induced seizures. Oxidative stress did play a small role in the myocardial damage as indicated by the small decrease in aconitase activity (P<0.05). Plasma IL-1α, IL-1β and TNF-α levels were significantly increased from 3-days post seizures. Haematoxylin & Eosin staining of ventricular sections revealed the formation of contraction bands, inflammation and oedema, confirming a structural pathology. Cardiac damage did not differ between i.p. and i.h. animals, suggesting cardiac damage following domoic acid results from CNS autonomic seizures and resultant sympathetic storm. This thesis has demonstrated, for the first time, that the cardiac pathology seen following domoic acid exposure is most likely to be a result of CNS activation and resultant seizure episodes, and is not a consequence of the direct interaction between domoic acid and the myocardium. We have also demonstrated for the first time, that seizure episodes result in chronic cardiac dysfunction and a structural pathology which is similar, but not identical to that seen following isoprotenerol administration in vivo.

The aim was to investigate associations of fitness and types and levels of physical activity with subsequent risk of cardiovascular disease. Four large-scale longitudinal cohort studies were used. The exposures were different measures related to physical activity and the outcomes were obtained through linkage to the Swedish In-Patient Register. In a cohort of 466 elderly men without pre-existing cardiovascular disease, we found that skeletal muscle morphology was associated with risk of cardiovascular events. A high amount of type I (slow-twitch, oxidative) skeletal muscle fibres was associated with lower risk of cardiovascular events and high amount of type IIx was associated with higher risk of cardiovascular events. This association was only seen among physically active men. Among 39,805 participants in a fundraising event, higher levels of both total and leisure time physical activity were associated with lower risk of heart failure. The associations were strongest for leisure time physical activity. In a cohort of 53,755 participants in the 90 km skiing event Vasaloppet, a higher number of completed races was associated with higher risk of atrial fibrillation and a higher risk of bradyarrhythmias. Further, better relative performance was associated with a higher risk of bradyarrhythmias. Among 1,26 million Swedish 18-year-old men, exercise capacity and muscle strength were independently associated with lower risk of vascular disease. The associations were seen across a range of major vascular disease events (ischemic heart disease, heart failure, stroke and cardiovascular death). Further, high exercise capacity was associated with higher risk of atrial fibrillation and a U-shaped association with bradyarrhythmias was found. Higher muscle strength was associated with lower risk of bradyarrhythmias and lower risk of ventricular arrhythmias. These findings suggest a higher rate of atrial fibrillation with higher levels of physical activity. The higher risk of atrial fibrillation does not appear to lead to a higher risk of stroke. In contrast, we found a strong inverse association of higher exercise capacity and muscle strength with vascular disease. Further, high exercise capacity and muscle strength are related to lower risk of cardiovascular death, including arrhythmia deaths. From a population perspective, the total impact of physical activity on cardiovascular disease is positive.

Heart failure (HF) is one of the top causes of mortality in the United States and globally. In order to combat the high mortality rates of this disease, medical technology, including internal cardioverter defibrillators (ICD) and left ventricular assist devices (LVAD), have become one of the most common treatments. Over the past 10 years the utilization of these cardiac devices has increased exponentially, which has created a new phenomenon of how we discuss death with patients who have one of these devices. The purpose of this dissertation is to increase understanding of the end-of-life decision making processes and current experiences that patients with a cardiac device are having. This dissertation includes four original manuscripts that focus on patients with a cardiac device and their experiences with decision-making at the end-of-life. The first paper is a data-based paper that examines experiences of patients with an ICD and what factors are associated with having a conversation with their providers about end-of-life. The second paper is an integrative review of the literature regarding what is currently known about end-of-life with an LVAD. The third paper is a psychometric evaluation of the Control Attitudes Scale-Revised (CAS-R) for patients with an LVAD. The fourth paper is a data-based manuscript that looks at patients with an LVAD and their attitudes and experiences with end-of-life conversations with providers and next-of-kin and the impact of cognition on these attitudes and experiences. The findings of this dissertation will hopefully inform providers of patients with cardiac devices about their patients end-of-life decision making processes. It will also demonstrate the gaps that are currently in practice, and ideally be able expand on how to assist patients and providers on improving communication about end-of-life decision making.

Ischaemic heart disease (IHD) is the leading cause of death worldwide. Currently, even optimal medical therapies do not attenuate deterioration of the left ventricular (LV) function completely. Stem cell therapies, and recently cardiac stem cell therapies, have emerged as potential novel treatments for IHD. However, clinical evidence from randomised controlled studies has shown mixed results. Thus understanding what patient-related factors may affect the therapeutic performance of the cells may help improving treatment outcomes. The studies described in this thesis aim to understand how cardiac progenitor cells (CPCs) can re-vascularise ischaemic myocardium and promote functional repair of the heart. Resident CPCs were isolated and expanded from the right atrial appendage of 68 patients following the ‘cardiosphere’ method (cardiosphere-derived cells or CDCs). They resemble mesenchymal progenitors as they lack the expression of endothelial and haematopoietic cell surface markers but express mesenchymal progenitor cell markers (e.g. CD105, CD90). Cell function was evaluated by support of angiogenesis, mesenchymal lineage differentiation potential in vitro, and improvement in heart function in vivo. Notably in vitro, CDC from different patients differed in their angiogenic supportive and differentiation potentials. In a rodent model of myocardial infarction (MI), transplantation of CDC reduced infarct size significantly (p<0.05). However, only those CDCs with a robust pro-angiogenic ability in vitro improved vessel density and heart systolic function (p<0.05) in vivo. A multiple regression model, which accounted for 51% of the variability observed, identified New York Heart Association (NYHA) class, smoking, hypertension, type of ischaemic disease and diseased vessel as independent predictors of angiogenesis. In addition, gene expression analyses revealed that differential gene expression of several extracellular matrix components (e.g. CUX1, COL1A2, BMP1 genes and microRNA-29b) could explain the differences observed in CDC’s vascular supportive function. In summary, this is the first description of variability in the pro-angiogenic and differentiation potential of CDCs and its correlation with their therapeutic potential. This study indicates that patient stratification may need to be included in the design of future trials to improve the efficacy of cell-based therapies.

Introduction: Some past breast cancer radiotherapy regimens led to an increased risk of death from heart disease. Although heart dose from breast cancer radiotherapy has generally reduced over the past few decades, there may still be some cardiac risk. Estimation of future risk for women irradiated today requires both measurement of their cardiac dose and dose-response relationships, which depend on cardiac dosimetry of past regimens, in conjunction with long-term follow-up data. Methods: Virtual simulation and computed tomography 3-dimensional treatment planning on a representative patient were used to estimate mean heart and coronary artery doses for women irradiated since 1950 in 71 randomised trials in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) overview. Patient-to-patient variability in cardiac dose was assessed. Heart and coronary artery doses were also calculated for breast cancer radiotherapy regimens used since the 1950s in Sweden. Cardiac doses from contemporary (year 2006) radiotherapy were assessed for 55 patients who received tangential breast cancer irradiation at a large UK radiotherapy centre. The maximum heart distance (i.e. the maximum distance between the anterior cardiac contour and the posterior tangential field edges) was measured for the left-sided patients, and its value as a predictor of cardiac doses assessed. Results: Mean heart dose for women irradiated in the EBCTCG trials varied from <1 to 18 Gray, and mean coronary artery dose from <1 to 57 Gray. Patient-to-patient variability was moderate. Mean heart dose for women irradiated in Sweden since the 1950s varied from <1 to 24 Gray, and mean coronary artery dose from <1 to 46 Gray. Heart dose from tangential irradiation has reduced over the past four decades. However, mean heart dose for left-sided patients irradiated in 2006 was 2 Gray and around half of them still received >20 Gray to parts of the heart and left anterior descending coronary artery. For these patients, maximum heart distance was a reliable predictor of cardiac doses. For the other patients, mean heart dose varied little and was usually less than 2 Gray. Conclusions: Cardiac doses from breast cancer radiotherapy can be estimated reliably and are now available for use in deriving dose-response relationships in the EBCTCG data and in a Scandinavian case-control study. Cardiac dose has reduced over the past four decades. Therefore the cardiac risk is also likely to have reduced. Nevertheless, for some patients, parts of the heart still receive >20 Gray in the year 2006.

Ischemic heart disease is a leading cause of death worldwide. Osteopontin (OPN), a cell-secreted extracellular matrix protein, is suggested to play a cardioprotective role in mouse models of ischemic heart disease. The objective of this study was to examine the role of OPN in modulation of systolic and diastolic functional parameters of the heart following mouse ischemia/reperfusion (I/R) injury. For this, wild-type (WT) and OPN-knockout (KO) mice aged approximately 4 months were subjected to cardiac ischemia for 45 minutes by the ligation of the left anterior descending coronary artery (LAD) followed by reperfusion of LAD by snipping the ligature. Heart function was measured using echocardiography at baseline, 1, 3, 7, 14, and 27 days post-I/R injury. M-mode echocardiographic images were used to calculate % fractional shortening [%FS], % ejection fraction [%EF], end-systolic volume [ESV], and end-diastolic volume [EDV], while pulsed wave Doppler images were used to measure aortic ejection time [AET], isovolumic relaxation time [IVRT], and total systolic time [TST]. Velocity of circumferential fiber shortening (Vcf) was calculated using FS and AET. I/R injury significantly decreased %EF and %FS in both WT and KO groups at all time points (1, 3, 7, 14, and 27 days post-I/R) versus the baseline. However, the decrease in % EF and %FS was significantly greater in KO-I/R group versus WT-I/R at 3, 7, 14 and 27 days post-I/R. I/R-mediated increase in ESV and EDV were significantly greater in KO-MI group versus WT-MI 3 day post-I/R. AET was significantly higher in WT-I/R group 27 days post-I/R versus baseline. However, AET was significantly lower in KO-I/R group 3 and 27 days post-I/R versus WT-I/R. IVRT was significantly higher in KO-I/R group 27 days post-I/R vs baseline. However, IVRT was significantly lower in KO-I/R group 1 day post-I/R vs WT-I/R. TST remained unchanged in WT and KO groups post-I/R versus their respective baseline groups. However, TST was significantly lower in KO-I/R group versus WT-I/R at 3 days post-I/R. Vcf was significantly higher at basal levels in the KO versus WT mice. I/R injury decreased Vcf in both groups versus their baseline at all time-points. These data provide evidence that lack of OPN deteriorates systolic and diastolic functional parameters of the heart following I/R injury, suggesting a cardioprotective role of OPN in myocardial remodeling post-IR.

Cardiovascular disease is a large problem in the intensive care unit (ICU) due to its high prevalence in modern society. In the ICU, intensive monitoring is required to help diagnose cardiac and circulatory dysfunction. However, complex interactions between the patient, disease, and treatment can hide the underlying disorder. As a result, clinical staff must often rely on their skill, intuition, and experience to choose therapy, increasing variability in care and patient outcome. To simplify this clinical scenario, model-based methods have been created to track subject-specific disease and treatment dependent changes in patient condition, using only clinically available measurements. The approach has been tested in two pig studies on acute pulmonary embolism and septic shock and in a human study on surgical recovery from mitral valve replacement. The model-based method was able to track known pathophysiological changes in the subjects and identified key determinants of cardiovascular health such as cardiac preload, afterload, and contractility. These metrics, which can be otherwise difficult to determine clinically, can be used to help provide targets for goal-directed therapies to help provide deliver the optimal level of therapy to the patient. Hence, this model-based approach provides a feasible and potentially practical means of improving patient care in the ICU.

Both hypertrophied and failing hearts are characterised by pathological left ventricular (LV) remodelling, impaired myocardial energy status and alteration in substrate metabolism. Cardiac magnetic resonance imaging (CMR) and magnetic resonance spectroscopy (MRS) are powerful tools in the characterisation of these disease conditions. More recent techniques have allowed assessment of myocardial steatosis using ¹H-MRS and tissue oxygenation using blood oxygen level dependent (BOLD) CMR. In hypertrophy and heart failure, studies on steatosis and the relationship with other parameters such as myocardial function and fibrosis, especially in humans are limited. I therefore investigated the presence of steatosis in severe aortic stenosis (AS) and dilated cardiomyopathy (DCM), and further assessed its relation to contractile function. This study found that myocardial triglyceride (TG) content is increased in both symptomatic and asymptomatic AS patients (lipid/water ratio 0.89±0.42% in symptomatic AS; 0.75±0.36% in asymptomatic AS vs. controls 0.45±0.17%, both p<0.05) and DCM patients (lipid/ratio 0.64±0.44% vs. controls 0.40±0.13%, p=0.03). Circumferential strain was lower in both AS (-16.4±2.5% in symptomatic AS; -18.9±2.9% in asymptomatic AS vs. controls 20.7±2.0%, both p<0.05) and DCM patients (-12.3±3.4% vs. controls -20.9±1.7%, p<0.001). In AS, myocardial contractility is related to the degree of steatosis, and were both reversible following aortic valve replacement (AVR), lipid/water ratio 0.92±0.41% vs. pre AVR 0.45±0.17%, p=0.04 and circumferential strain -17.2±2.0% vs. pre AVR -19.5±3.2%, p=0.04. A novel finding of this study was significant correlation of MRS-measured TG content with histological staining of TG of the myocardium, taken from endomyocardial biopsy during AVR. In DCM, myocardial TG was independently associated with LV dilatation and correlated significantly with hepatic TG, which suggests that both cardiac and hepatic steatosis might be a common feature in the failing heart. Additionally, although the hypertrophied heart is characterised by impaired perfusion, it is unknown if this is severe enough to translate into tissue deoxygenation and ischaemia. I assessed this by using adenosine vasodilator stress test and BOLD-CMR in patients with severe AS. It was found that AS patients had reduced perfusion (myocardial perfusion reserve index-MPRI 1.0±0.3 vs. controls 1.7±0.3, p<0.001), and blunted tissue oxygenation (blood-oxygen level dependent-BOLD signal intensity-SI change 4.8±9.6% vs. controls 18.2±11.6%, p=0.001) during stress. Importantly, there was a substantial improvement in perfusion and oxygenation towards normal after AVR, MPRI 1.5±0.4, p=0.005 vs. pre AVR and BOLD SI change 16.4±7.0%, p=0.014 vs. pre AVR. Overall, the work in this thesis supports the powerful role of CMR in assessing LV function and elucidating metabolic mechanisms in the hypertrophied and failing heart.

Resumo: A insuficiência cardíaca, já denominada de epidemia do século XXI é, de entre as doenças cardiovasculares, a única cuja incidência e prevalência continuam a crescer, apesar dos imensos progressos feitos na área da terapêutica nas últimas duas décadas. Caracteriza-se por elevada mortalidade – superior à do conjunto das neoplasias malignas -, grande morbilidade, consumo de recursos e custos exuberantes. É um dos problemas mais graves de Saúde Pública dos Países industrializados, cujo manejo deverá constituir uma prioridade para os Serviços Nacionais de Saúde. Todavia, o reconhecimento universal da gravidade desta situação tem originado poucas soluções concretas para conter a epidemia, cujo protagonismo não cessa de aumentar. É possível hoje prevenir, tratar de forma a retardar a evolução da doença ou até revertê-la, desde que diagnosticada atempadamente. Qualquer atitude nestas áreas pressupõe um diagnóstico correcto, precoce e completo da situação, sem o qual não haverá um tratamento adequado. O diagnóstico tem preocupado bem menos os investigadores e os clínicos que a terapêutica. É, contudo, comprovadamente difícil a todos os níveis dos Cuidados de Saúde e constitui certamente a primeira barreira ao controlo da situação. OBJECTIVOS: À luz do conhecimento actual e da nossa própria experiência, propusemo-nos analisar os problemas do diagnóstico da insuficiência cardíaca e a forma como eles se repercutem no manejo da doença e na saúde das populações. Foram objectivos desta dissertação avaliar como a evolução dos modelos de insuficiência cardíaca e de disfunção ventricular influenciaram a definição e os critérios de diagnóstico da doença ao longo do tempo; as consequências geradas pela falta de consenso quanto à definição e aos critérios de diagnóstico nas diferentes fases de evolução desta entidade; discutir o papel da clínica e dos exames complementares no diagnóstico da síndrome e nas estratégias de rastreio da disfunção cardíaca; apontar alguns caminhos e possíveis metodologias para o manejo da doença de forma a que possamos, no futuro, diagnosticar melhor para melhor prevenir, tratar e conter a epidemia. METODOLOGIA: A metodologia utilizada neste trabalho decorre directamente da actividade assistencial diária e da investigação clínica gerada no interesse pelos problemas com que nos deparámos, ao longo dos anos, na área da insuficiência cardíaca. A par com o estudo epidemiológico da insuficiência cardíaca em Portugal, desenvolvemos um protocolo original para a avaliação da qualidade do diagnóstico no ambulatório e do papel da clínica e dos diferentes exames complementares no diagnóstico da síndrome. Avaliámos os problemas do diagnóstico da insuficiência cardíaca em meio hospitalar através de um inquérito endereçado aos Directores de Serviço, pelo Grupo de Estudo de Insuficiência Cardíaca da Sociedade Portuguesa de Cardiologia. Analisámos a qualidade do diagnóstico da insuficiência cardíaca codificado à data da alta hospitalar. Após a criação de uma área específica, vocacionada para o internamento de doentes com insuficiência cardíaca, avaliámos o seu impacto no diagnóstico e tratamento da síndrome. Também testámos o desempenho dos peptídeos natriuréticos no diagnóstico dos diferentes tipos de insuficiência cardíaca sintomática, em meio hospitalar. Os resultados parciais da investigação clínica foram sendo comunicados à comunidade científica e publicados em revistas da especialidade. Discutimos, nesta dissertação, os artigos publicados e em publicação, à luz do estado actual da arte na área do diagnóstico. Reflectimos sobre as consequências das dificuldades no diagnóstico da insuficiência cardíaca e apontamos possíveis caminhos para implementar o rastreio. RESULTADOS: Em 1982, muito no início da nossa actividade clínica, cientes da complexidade da insuficiência cardíaca e do desafio que a sua abordagem constituía para os clínicos,empenhávamo-nos no desenvolvimento de uma classificação fisiopatológica original da insuficiência cardíaca, que foi tema para a Tese de Doutoramento da Professora Doutora Fátima Ceia em 1989. sistemático da doença, melhorar os cuidados prestados aos doentes e diminuir os custos envolvidos no manejo da síndrome. No artigo 1 – Insuficiência cardíaca: novos conceitos fisiopatológicos e implicações terapêuticas – publicado em 1984, descrevemos, à luz do conhecimento da época, a insuficiência cardíaca como uma doença sistémica, resultado da interacção entre os múltiplos mecanismos de compensação da disfunção cardíaca. Desenvolvemos “uma classificação fisiopatológica com implicações terapêuticas” original, onde delineámos os diferentes tipos de insuficiência cardíaca, as suas principais características clínicas, hemodinâmicas, funcionais e anatómicas e propuzemos terapêutica individualizada de acordo com a definição e o diagnóstico dos diferentes tipos de insuficiência cardíaca. Em 1994, no artigo 2 – A insuficiência cardíaca e o clínico no fim do século vinte – salientamos a forma como os diferentes mecanismos de compensação interagem, influenciam a evolução da doença no tempo, produzem síndromes diferentes e fundamentam a actuação terapêutica. Discutimos a evolução da definição da doença de acordo com o melhor conhecimento da sua fisiopatologia e etiopatogenia. Sublinhamos a necessidade de desenvolver estratégias para a prevenção da doença, o diagnóstico precoce e o tratamento atempado. Ainda no primeiro capítulo: Insuficiência cardíaca: da fisiopatologia à clínica – um modelo em constante evolução – revisitámos os sucessivos modelos fisiopatológicos da insuficiência cardíaca: cardio-renal, hemodinâmico, neuro-hormonal e imuno-inflamatório e a sua influência na definição da síndrome e nos critérios de diagnóstico. Analisámos a evolução do conceito de disfunção cardíaca que, à dicotomia da síndrome em insuficiência cardíaca por disfunção sistólica e com função sistólica normal, contrapõe a teoria do contínuo na evolução da doença. Esta última, mais recente, defende que estas duas formas de apresentação não são mais do que fenótipos diferentes, extremos, de uma mesma doença que origina vários cenários, desde a insuficiência cardíaca com fracção de ejecção normal à disfunção sistólica ventricular grave No capítulo II - O diagnóstico da insuficiência cardíaca: problemas e consequências previsíveis - analisamos as consequências da falta de critérios de diagnóstico consensuais para a insuficiência cardíaca em todo o seu espectro, ao longo do tempo. As dificuldades de diagnóstico reflectem-se nos resultados resultados dos estudos epidemiológicos. Vivemos essa dificuldade quando necessitámos de definir critérios de diagnóstico exequíveis no ambulatório, abrangendo todos os tipos de insuficiência cardíaca e de acordo com as Recomendações, para o programa EPICA –EPidemiologia da Insuficiência Cardíaca e Aprendizagem – desenhado para os Cuidados Primários de Saúde. No artigo 3 – Epidemiologia da insuficiência cardíaca e Aprendizagem – desenhado para os Cuidados Primários de Saúde. No artigo 3 – Epidemiologia da insuficiência cardíaca – discutimos as consequências dos grandes estudos epidemiológicos terem adoptado ao longo dos anos definições e critérios de diagnóstico muito variáveis,conduzindo a valores de prevalência e incidência da doença por vezes também muito diferentes. O problema agudiza-se quando se fala em insuficiência cardíaca com fracção de ejecção normal ou com disfunção diastólica, ou ainda em rastreio da disfunção cardíaca assintomática, situações para as quais tem sido extraordinariamente difícil consensualizar critérios de diagnóstico e estratégias. É notória a ausência de grandes estudos de terapêutica no contexto da insuficiência cardíaca com fracção de ejecção normal ou com disfunção diastólica que, à falta de Recomendações terapêuticas baseadas na evidência, continuamos a tratar de acordo com a fisiopatologia. Assim, discrepâncias provavelmente mais relacionadas com os critérios de diagnóstico utilizados do que com diferenças reais entre as populações, dificultam o nosso entendimento quanto ao real peso da insuficiência cardíaca e da disfunção ventricular assintomática. Também comprometerão certamente a correcta alocação de recursos para necessidades que, na realidade, conhecemos mal. O artigo 4 – Prévalence de l’ insuffisance cardiaque au Portugal – apresenta o desenho dos estudos EPICA e EPICA-RAM. O EPICA foi dos primeiros estudos a avaliar a prevalência da insuficiência cardíaca sintomática global, na comunidade, de acordo com os critérios da Sociedade Europeia de Cardiologia. Definimos critérios ecocardiográficos de disfunção cardíaca para todos os tipos de insuficiência cardíaca, nomeadamente para as situações com fracção de ejecção normal, numa época em que ainda não havia na literatura Recomendações consensuais. No artigo 5 – Prevalence of chronic heart failure in Southwestern Europe: the EPICA study - relatamos a prevalência da insuficiência cardíaca em Portugal con-supra-diagnosticada em 8,3%. A codificação hospitalar falhou uma percentagem significativa de doentes com insuficiência cardíaca, minimizando assim o peso da síndrome, com eventual repercussão na alocação dos recursos necessários ao seu manejo no hospital e para a indispensável interface com os Cuidados Primários de Saúde. No artigo 8 – Tratamento da insuficiência cardíaca em hospitais portugueses: resultados de um inquérito – todos os inquiridos relataram dificuldades no diagnóstico atempado da insuficiência cardíaca. Os Directores dos Serviços de Cardiologia reclamam mais recursos humanos vocacionados e estruturas hospitalares especializadas no diagnóstico e tratamento da síndrome, enquanto que os Directores dos Serviços de Medicina necessitam de facilidades de acesso aos métodos complementares de diagnóstico como a ecocardiografia e de maior apoio do Cardiologista. As dificuldades no diagnóstico da insuficiência cardíaca,a todos os níveis de cuidados, acarretam assim consequências epidemiológicas, sócio-económicas e financeiras nefastas para o doente individual, a planificação do Sistema Nacional de Saúde e para a Saúde Pública No capítulo III relembramos a importância do diagnóstico completo da insuficiência cardíaca que, para além do diagnóstico sindromático e anatomo-funcional, deverá incluir o diagnóstico etiológico, e das comorbilidades. Muitos destes aspectos podem comprometer a interpretação dos exames complementares de diagnóstico e, não raramente, as indicações dos fármacos que influenciam a sobrevida dos doentes, a estratégia terapêutica e o prognóstico da síndrome Conscientes das dificuldades no diagnóstico da insuficiência cardíaca nos Cuidados Primários de Saúde e do papel preponderante dos especialistas em Medicina Familiar na contenção da epidemia, propusemo-nos, como objectivos secundários do estudo EPICA (artigo 5), investigar a acuidade diagnóstica dos instrumentos à disposição daqueles colegas, na prática clínica diária: a clínica e os exames complementares de diagnóstico de primeira linha. O artigo 10 – The diagnosis of heart failure in primary care: value of symptoms and signs - documenta o valor limitado dos sinais, sintomas e dados da história pregressa, quando usados isoladamente, no diagnóstico da síndrome. Todos têm baixa sensibilidade para o diagnóstico. Têm maior valor preditor os associados às situações congestivas, mais graves: a dispneia paroxística nocturna (LR 35,5), a ortopneia (LR 39,1), a dificuldade respiratória para a marcha em plano horizontal (LR 25,8), o ingurgitamento jugular > 6 cm com hepatomegalia e edema dos membros inferiores (LR 130,3), que estão raramente presentes na população de insuficientes cardíacos do ambulatório (sensibilidade <10%). O galope ventricular (LR 30,0), a taquicardia >110ppm (LR 26,7) e os fervores crepitantes (LR 23,3) também estão associados ao diagnóstico, mas são também pouco frequentes na população estudada (sensibilidade < 36%). São ainda preditores do diagnóstico o tratamento prévio com digitálico (LR 24,9) e/ou com diurético (LR 10,6), uma história prévia de edema pulmonar agudo (LR 54,2) ou de doença das artérias coronárias (LR 7,1). No artigo 11- Aetiology, comorbidity and drug therapy of chronic heart failure in the real world: the EPICA substudy - confirmámos que a hipertensão arterial é, de entre os factores de risco e/ou etiológicos, a causa mais frequente de insuficiência cardíaca no ambulatório, em Portugal (80%). Trinta e nove por cento dos doentes do estudo EPICA têm história de doença coronária e 15% de fibrilhação auricular. Quantificámos a comorbilidade e analisámos a sua potencial influência no facto da prescrição terapêutica estar aquém das Recomendações internacionais em Portugal, como aliás em toda a Europa. No artigo 12 - The value of electrocardiogram and X-ray for confirming or refuting a suspected diagnosis of heart failure in the community – demonstrámos que os dados do ECG e do RX do tórax não permitem predizer o diagnóstico de insuficiência cardíaca na comunidade; 25% dos doentes com insuficiência cardíaca objectiva tinham ECG ou RX do tórax normais. No artigo 13 - Evaluation of the performance and concordance of clinical questionnaires for heart failure in primary care - comparámos sete questionários e sistemas de pontuação habitualmente utilizados nos grandes estudos, para o diagnóstico da insuficiência cardíaca. Mostraram ter, na sua maioria, uma concordância razoável ou boa entre si. Foram muito específicos (>90%) mas pouco sensíveis. Aumentaram a probabilidade do diagnóstico de 4,3% pré-teste para 25 a 30% pós-teste. Revelaram-se um melhor instrumento para a exclusão da causa cardíaca dos sintomas do que para o diagnóstico da síndrome O artigo 14 - Epidemiologia da insuficiência cardíaca em Portugal continental: novos dados do estudo EPICA – compara as características dos doentes com suspeita clínica, não comprovada, de insuficiência cardíaca (falsos positivos), com os casos de insuficiência cardíaca. Os primeiros são mais idosos, mais mulheres, com mais excesso de peso, menos história de doença das artérias coronárias. Confirma ainda que a clínica, o ECG e o Rx tórax não permitem diferenciar os doentes com insuficiência cardíaca por disfunção sistólica ventricular daqueles que têm fracção de ejecção normal. Perante o desafio do diagnóstico da insuficiência cardíaca com fracção de ejecção normal, as dificuldades de acesso à ecocardiografia na comunidade e os custos acrescidos do exame, pretendemos averiguar no artigo 15 - The diagnostic challenge of heart failure with preserved systolic function in primary care setting: an EPICA-RAM sub-study - o desempenho do BNP no rastreio dos doentes com a suspeita clínica do diagnóstico, a enviar para ecocardiografia. Testámos o desempenho do teste como preditor do diagnóstico clínico da insuficiência cardíaca com função sistólica preservada, bem como dos indicadores ecocardiográficos de disfunção diastólica utilizados no estudo: dilatação da aurícula esquerda e hipertrofia ventricular esquerda. O teste apenas foi bom preditor da dilatação da aurícula esquerda, mas não do diagnóstico clínico deste tipo de insuficiência cardíaca, nem da presença de hipertrofia ventricular esquerda diagnosticada por ecocardiografia (área abaixo da curva ROC: 0,89, 0,56 e 0,54 respectivamente). Concluímos que, isoladamente, não será um bom método de rastreio da doença na comunidade, nem poderá substituir o ecocardiograma no doente com a suspeita clínica do diagnóstico, pelo menos nas fases precoces, pouco sintomáticas da doença. Estudámos e comparámos o desempenho dos peptídeos natriuréticos do tipo B - BNP e NT-proBNP - no diagnóstico da insuficiência cardíaca sintomática, por disfunção sistólica e com fracção de ejecção preservada, no internamento hospitalar. Avaliámos doentes e voluntários normais, de forma a estabelecermos os cut-off do nosso laboratório. Relatámos os resultados deste trabalho no artigo 16 – Valor comparativo do BNP e do NT-proBNP no diagnóstico da insuficiência cardía-ca. Ambos os testes tiveram um excelente desempenho no diagnóstico da insuficiência cardíaca sintomática, em meio hospitalar, mas nenhum foi capaz de diferenciar a insuficiência cardíaca com disfunção sistólica ventricular da que tem fracção de ejecção normal Revimos, à luz do conhecimento actual, o desempenho dos diferentes exames complementares, nomeadamente dos peptídeos natriuréticos e da ecocardiografia, no diagnóstico da insuficiência cardíaca sintomática global, por disfunção sistólica ventricular e com fracção de ejecção normal e discutimos os critérios mais recentemente propostos e as últimas Recomendações internacionais Discutimos as estratégias propostas para o rastreio da disfunção ventricular assintomática que é, na comunidade, pelo menos tão frequente quanto a sintomática. Existe evidência de que tratar precocemente a disfunção ventricular sistólica assintomática se traduz em benefícios reais no prognóstico e, tal como no caso da disfunção sistólica sintomática, é custo-eficiente. Autilização do método padrão para o rastreio da disfunção cardíaca na população obrigaria à realização de ecocardiograma a todos os indivíduos, o que é técnica e economicamente incomportável. Vários estudos têm vindo a testar diversas estratégias alternativas, na procura de uma metodologia que seja, também ela, custo-eficiente. Os autores são unânimes no aspecto em que nenhum exame, quando avaliado isoladamente, foi útil para o rastreio da disfunção cardíaca. Contudo apontam para o ECG e/ou os peptídeos natriuréticos, integrados ou não em esquemas de pontuação clínica, como testes úteis para o pré-rastreio para ecocardiografia. Permitem diminuir os pedidos de ecocardiograma e os custos do rastreio, que se torna tão custo-efectivo quanto o do cancro da mama ou do colo do útero. Alguns autores preconizam ainda a avaliação qualitativa da disfunção cardíaca por ecocardiograma portátil, no contexto de ECG anómalo ou de peptídeo natriurético elevado, antes da referenciação para o ecocardiograma completo. Apontam esta estratégia como sendo a mais custo-eficiente para o rastreio da disfunção cardíaca. Finalmente, tecemos alguns comentários finais quanto a perspectivas de futuro para o manejo da insuficiência cardíaca. É premente estabelecer uma definição precisa e universal da síndrome e critérios de diagnóstico consensuais, claros, objectivos, simples e reprodutíveis para todo o espectro da insuficiência cardíaca, para que possamos num futuro próximo avaliar de forma correcta a extensão do problema, organizar cuidados médicos eficientes e acessíveis a todos e melhorar o prognóstico dos doentes, numa política imprescindível e inevitável de contenção dos custos. Perante os problemas de diagnóstico da síndrome no ambulatório, consideramos ser necessário implementar programas de formação continuada e facilitar o diálogo e a colaboração entre Cuidados Primários de Saúde e Unidades especializadas no manejo da doença, à imagem do que fizemos pontualmente aquando do programa EPICA e do que está a ser desenvolvido em vários países europeus e nos Estados Unidos da América, sob a forma de redes alargada de prestação de cuidados, para a insuficiência cardíaca. As clínicas de insuficiência cardíaca, a laborar sobretudo em meio hospitalar, já deram provas quanto à maior conformidade do diagnóstico (e tratamento) de acordo com as Recomendações, assim como na melhoria da qualidade de vida e sobrevida dos doentes. No artigo 17 - Implementar as Recomendações na prática clínica: benefícios de uma Unidade de Insuficiência Cardíaca Aguda - relatamos a nossa experiência quanto à melhoria da qualidade dos cuidados prestados, nas áreas do diagnóstico e tratamento, numa unidade funcional dedicada ao internamento dos doentes com insuficiência cardíaca aguda. Defendemos que estas áreas específicas de internamento se devem articular com outras,nomeadamente hospitais de dia de insuficiência cardíaca, podendo ou devendo até ser diferentes na sua estrutura e recursos, de acordo com as necessidades das populações no seio das quais são implementadas. Cabe-lhes um papel determinante na interacção com os Cuidados Primários de Saúde, na formação médica continuada e de outros profissionais de saúde e na recepção e orientação dos doentes referenciados para a especialidade.São ainda necessários esforços redobrados para a identificação e controlo dos factores de risco e para o estabelecimento de estratégias de rastreio da disfunção ventricular na comunidade. Tal é passível de ser feito e é custo-eficiente, mas exige a colaboração de técnicos de saúde, investigadores e poder político para avaliar das necessidades reais, implementar e controlar a qualidade destas estratégias, sem as quais não conseguiremos conter a epidemia. SUMMARY: Despite there has been substantial progress in the treatment of heart failure over the last several decades, it is the only cardiovascular disorder that continues to increase in both prevalence and incidence. Characterised by very poor survival and quality of life heart failure is responsible for among the highest healthcare costs for single conditions in developed countries. Heart failure is therefore becoming an increasing concern to healthcare worldwide and must be a priority to National Health Services. It is already called the epidemic of the 21 st century. A correct diagnosis is the cornerstone leading to effective management of the syndrome. An early, accurate and complete diagnosis has become crucial with the identification of therapies that can delay or reverse disease progression and improve both morbidity and mortality. Diagnostic methods may need to encompass screening strategies, as well as symptomatic case identification. Until now, investigation has been over focused on pharmacological treatment; relatively little work has been done on assessing diagnostic tools. This is actually a difficult condition to diagnose at all levels of care, and misdiagnosis must be the first barrier to the control of the epidemic. AIMS Considering current and up-dated knowledge and ourown experience we analyse the problems in diagnosing heart failure and cardiac dysfunction and how they affect patient’s clinical outcome and public health care. It was our aim to analyse how increasing knowledge about cardiac dysfunction influenced the concept of heart failure, its definition and diagnostic criteria; the problems resulting from the use of non consensual definitions and diagnostic criteria; the role of clinical data and diagnostic tests on the diagnosis of the syndrome and on the screening for cardiac dysfunction in the community; to discuss best strategies to enhance diagnostic management of heart failure in all its spectrum, in order to halt the epidemic in the near future. METHODS: The investigation on which the present dissertation is based was developed progressively, along the years, during our every-day clinical practice. Various original clinical investigations and review papers, related to challenges in heart failure management and especially to diagnosis, were presented in scientific meetings and/or published gradually as partial results were obtained. The EPICA Programme (epidemiology of heart failure and awareness), a large-scale epidemiological study on heart failure in Portugal, addressed as secondary endpoints, problems of heart failure misdiagnosis in primary care and the value of clinics and different diagnostic tests to confirme or refute the diagnosis of the syndrome suspected on clinical grounds. But problems on the diagnosis of heart failure are not confined to primary care. Therefore, under the auspices of the Working Group of Heart Failure of the Portuguese Society of Cardiology, a survey on the management of heart failure at hospital was addressed to the heads of Portuguese Cardiology and Internal Medicine Wards. Compliance with Guidelines on diagnosis and treatment of heart failure, perceived difficulties and requests to a better management of the syndrome were ascertained. We have then explored the validity of a coded diagnosis of heart failure at death/discharge from the Department of Medicine of S. Francisco Xavier Hospital, and the rate of misdiagnosis. Gains on compliance with Guidelines on the diagnosis and treatment of heart failure, before and after the implementation of an acute heart failure unit in this Department were assessed. We also compared the performance of type-B natriuretic peptides – BNP and NT-proBNP – on systolic and diastolic heart failure diagnosis, in order to implement the more adequate test. In this thesis we discuss our published papers against the state of the art on heart failure diagnosis, and actual consequences of misdiagnosing. We revisit the accuracy of the different diagnostic testes to a definite diagnosis of the disease. Finally we analyse the different ways of screening for cardiac TESE3 AF 6/9/08 12:25 PM Page 309 310 Summary dysfunction and the more cost-efficient strategies to enhance heart failure diagnosis and management. RESULTS Since 1982, at the very beginning of our clinical activity, already aware of the complexity of the management of heart failure, we were involved in the development of an original pathophysiological heart failure classification, theme of Professor Fátima Ceia Doctoral Thesis discussed in 1989. Paper 1 - Heart Failure. New pathophysiological approach to therapy – published in 1984, described heart failure as a systemic disease resulting from the interaction of the different compensatory mechanisms. We proposed a new dynamic, pathophysiological and aetiological approach to the diagnosis of heart failure syndromes, based on clinics and conventional non-invasive assessment with drug management implications. In 1994, in paper 2 – Heart failure and the physician - towards the XXI century – we discussed the way how the compensatory mechanisms interact, produce the different heart failure syndromes and affect the evolution of the disease. Changing definitions according to the knowledge of the pathophysiology of heart failure at that time were revisited. The need for a universally accepted definition leading to early and accurate diagnosis and treatment of the syndrome was pointed-out. We called for strategies to prevent heart failure. In an up-dated review titled: Heart failure: from pathophysiology to clinics – a model in constant evolution – we revisit the changing pathophysiological models of heart failure – cardio-renal, haemodynamic, neuro-hormonal and imuno-inflamatory models - and their influence on the definition of the syndrome. Traditional dicotomization of heart failure in systolic and diastolic dysfunction is discussed. Rather than being considered as separate diseases with a distinct pathophysiology, systolic and diastolic heart failure may be merely different clinical presentations within a phenotypic spectrum of one and the same disease. Implications for the definition and diagnosis of heart failure are self evident. In chapter II – The diagnosis of heart failure: problems and foreseeable consequences - we analyse epidemiological, clinical and financial consequences of non consensual definition and diagnostic criteria of heart failure for individual patients, Healthcare Systems and Public Health. Problems resulting from the absence of a universally accepted definition of heart failure are clearly illustrated by current epidemiological data and were revisited in paper 3 – Epidemiology of heart failure. In various epidemiological studies measured prevalence and incidence of the syndrome diverge significantly. This worrying variation is certainly more due to different definitions and used diagnostic criteria than true differences between populations. We faced these difficulties when we had to design the EPICA programme, a large population-based study where we had to define simple, effective and easy to obtain diagnostic criteria of heart failure, for the whole spectrum of the disease, in primary care setting. The problem grew when we focused on heart failure with normal ejection function where diagnostic criteria were far from consensual. Therefore large trials on heart failure with normal ejection fraction and consensual evidence-based Guidelines on diagnosis and treatment of diastolic heart failure are still missing. Paper 4 – Prevalence of heart failure in Portugal - presents the design of the EPICA Programme. The EPICA study was one of the first large epidemiological studies addressing the prevalence of global heart failure, in the community, according to the European Guidelines for the diagnosis of the syndrome. We had to define simple, precise echocardiographic criteria to confirm a suspected diagnosis of heart failure on clinical grounds, in all its spectrum. At that time, Guidelines for heart failure with normal ejection fraction where far from consensual and non applicable to the ambulatory. In paper 5 - Prevalence of heart failure in Southwestern Europe: the EPICA study - we reported the prevalence of heart failure in mainland Portugal. From 5434 attendants of primary care centres, representative of the Portuguese population above 25 years, 551 had heart failure, leading to a prevalence of global heart failure of 4.35%, increasing sharply with age in both genders; 1.36% had systolic dysfunction and 1.7% normal ejection fraction. TESE3 AF 6/9/08 12:25 PM Page 310 Summary 311 In paper 6 – Epidemiology of heart failure in primary care in Madeira: the EPICA-RAM study - we report an overall prevalence of heart failure of 4.69%, with systolic dysfunction in 0.76% and with a normal ejection fraction in 2.74% of the cases. Discrepancies in the prevalence of the different types of heart failure between mainland and Madeira are probably related to different Public Health Care organization. Both studies showed that only half of the patients with a suspected diagnosis of heart failure on clinical grounds had the diagnosis confirmed by objective evidence of cardiac dysfunction. It’s therefore probable that unnecessary drugs were prescribed to patients who didn’t need them while others, who would benefit, were not correctly treated for heart failure. Paper 7 – Diagnosis of heart failure in primary care – is a review of the state of the art of the diagnosis of heart failure in primary care setting. It focused on main challenges faced by primary care physicians, namely difficulties on the access to imaging and strategies to screen for cardiac dysfunction. General practitioners awareness and training on the diagnosis and treatment of the syndrome are crucial to halt the epidemic. But problems on the diagnosis of heart failure are not exclusive of primary care. Heart failure is the first cause of hospitalization of patients above 65 years in medical wards, and accounts for more than 70% of the costs with the syndrome. In paper 9 – Validity of a diagnosis of heart failure: implications of misdiagnosing – we reported a prevalence of heart failure in patients hospitalized in our Medicine Department, during a six month period, of 17%. The diagnosis was actually sub-coded at death /discharge. The accuracy of the death / discharge coded diagnosis was 72.2%; the syndrome was under-diagnosed in 21.1% of the cases and over-diagnosed in 8.3%. The discharge codes failed a significant percentage of heart failure cases, biased the actual burden of the syndrome and compromise the allocation of resources to manage in-hospital heart failure and to develop specialised programmes of interaction with primary care. In paper 8 – Treatment of heart failure in Portuguese hospitals: results of a questionnaire – everybody reported difficulties in the management of heart failure. Heads of Cardiology Wards needed more specialised physicians and nurses as well as specific heart failure units for the management of the syndrome, and Heads of Internal Medicine Wards demand more facilities, easier access to echocardiography, and support from heart failure specialised cardiologists. Difficulties in the diagnosis of heart failure at all levels of care, have huge epidemiological, clinical and economic consequences for the individual patient, National Health Services and Public Health. In chapter III, we revisit the relevance of a complete diagnosis of heart failure. An appraisal based on symptoms alone is clearly an incomplete and inaccurate representation of the severity of cardiovascular disease. Determination of cardiac status requires evaluation of composite etiologic, anatomic, and physiologic diagnoses. Functional class and comorbidities must complement the diagnosis, leading to the more appropriate and individualized treatment. Aware of the uncertainty of the diagnosis of heart failure in primary care setting and of the role of General Practitioners in the management of the syndrome, we have evaluated in pre-specified substudies of the EPICA programme, the accuracy of clinics and tests available to the diagnosis of heart failure in the community. Paper 10 – The diagnosis of heart failure in primary care: value of symptoms and signs – confirmed that symptoms and signs and clinical history have limited value in diagnosing heart failure when used alone. The signs and symptoms that best predicted a diagnosis of heart failure were those associated with more severe disease. Among current symptoms, the history of paroxysmal nocturnal dyspnoea (LR 35.5), orthopnea (LR 39.1) and dyspnoea when walking on the flat (LR 25.8) were associated with a diagnosis of heart failure. However, these symptoms were not frequent within this population (sensitivity < 36%). Jugular pressure > 6 cm with hepatic enlargement, and oedema of the lower limbs (LR 130.3), a ventricular gallop (LR 30.0), a heart rate above 110 bpm (LR 26.7), and rales (LR 23.3), were all associated with a diagnosis of heart failure but TESE3 AF 6/9/08 12:25 PM Page 311 312 Summary were infrequent findings (sensitivity < 10%). Prior use of digoxin (LR 24.9) and/or diuretics (LR 10.6), an history of coronary artery disease (LR 7.1) or of pulmonary oedema (LR 54.2) were also associated with a greater likelihood of having heart failure. In paper 11 – Aetiology, comorbidity and drug therapy of chronic heart failure in the real world: the EPICA substudy – aetiological features and therapy relevant comorbidities were analysed. Hypertension was the more frequent risk factor/aetiology of heart failure in the community in Portugal (about 80%). Thirty nine percent had an history of coronary artery disease, and 15% had atrial fibrillation. In paper 12 – The value of electrocardiogram and X-ray for confirming or refuting a suspected diagnosis of heart failure in the community – we reported that ECG and X-ray features are not sufficient to allow heart failure to be reliably predicted in the community. Twenty five percent of patients with heart failure had a normal ECG or chest X-ray. In paper 13 – Evaluation of the performance and concordance of clinical questionnaires for heart failure in the primary care – we compared the accuracy of seven clinical questionnaires and scores for the diagnosis of heart failure in the community, and their concordance. Concordance was good between most of the questionnaires. Their low sensibility impairs their usefulness as diagnostic instruments, but their high specificity (>90%) makes them useful for the identification of patients with symptoms and signs from non-cardiac cause. In paper 14 – Epidemiology of heart failure in mainland Portugal: new data from the EPICA study -characteristics of patients with a definite diagnosis of heart failure and of those in whom the diagnosis of heart failure suspected on clinical grounds was excluded (false positive) were compared. The laters were older, more frequently women, had excessive weight, and a history of coronary artery disease was less frequent. Clinics, ECG and chest X-ray could not distinguish patients with heart failure due to systolic dysfunction from those with normal ejection fraction. Considering the limited and costly access to echocardiography in the community we address in paper 15 - the diagnostic challenge of heart failure with preserved systolic function in primary care: an EPICA-RAM substudy. The performance of BNP as a predictor of a diagnosis of heart failure with preserved systolic function according to ESC Guidelines, left ventricular hypertrophy and dilated left atria by echocardiography was tested. BNP was a good predictor of a dilated left atria, but not of the diagnosis of heart failure with preserved systolic function or of left ventricular hypertrophy (AUC: 0.89, 0.56, and 0.54 respectively). We conclude that BNP measurement alone was not a suitable screening test for heart failure with normal ejection fraction in the community, at least in patients with no or mild symptoms.In paper 16 – Comparative value of BNP and NTproBNP on the diagnosis of heart failure – we first established normal values and cut-offs for our laboratory.Then we assess the diagnostic accuracy of both peptides for the in-hospital diagnosis of heart failure due to systolic dysfunction and with normal ejection fraction. BNP and NT-proBNP had an excellent and similar accuracy to the diagnosis of both types of symptomatic heart failure, but none could distinguish patients with systolic heart failure from those with normal ejection fraction. We revisited the role of the various tests on the diagnosis of heart failure with systolic dysfunction, and with normal ejection fraction and discussed the more recent International Guidelines. There is a great piece of evidence that early treatment of asymptomatic left ventricular systolic dysfunction is cost-effective. Therefore, several screening strategies were investigated. ECG and type B natriuretic peptides measurements, alone or as part of clinical scores, allowed cost-effective community-based screening for left ventricular systolic dysfunction, especially in high-risk subjects. A programme including hand-held echocardiography, following NT-proBNP or ECG pre-screening prior to traditional echocardiogram was the most cost-effective.Screening strategies for left ventricular dysfunction proved no more costly than existing screening programmes such as those for cervical or breast cancer. Conversely, as far as we know, there is no proven strategy to efficiently screen for diastolic dysfunction in the community.Finally we discuss perspectives for heart failure TESE3 AF 6/9/08 12:25 PM Page 312 Summary 313 management in the near future. Simple, reliable and consensual diagnostic procedures are crucial to evaluate the actual burden of the disease, to comply with Guidelines and to reduce healthcare utilisation and costs. As the management of the syndrome in primary care has been hampered by perceived difficulties in diagnosis, improving diagnostic skills is essential and remains a continuous challenge for primary care clinicians. Moreover, patients may require more investigations and treatments that may not be available or very familiar to General Practitioners. Shared care is therefore necessary. Disease management programmes when available and accessible, are the preferred choice to address this issue. This multidisciplinary model of care delivered in specialized heart failure clinics, heart failure day hospitals and many other heart failure care stru-ctures, have shown success in improving quality of life, and reducing morbi-mortality and costs. In paper 17 - Translating Guidelines into clinical practice: benefits of an acute heart failure unit - we report a better compliance with Guidelines on diagnosis and treatment of heart failure after the implementation of a specialized heart failure unit in our Internal Medicine Department. We defend the implementation of heart failure programme management networks to provide optimal care for both patients and health care providers. They may consist of different structures to better address the needs of the referred patient, the referral physician and the regional health care system, and should have a crucial role in transition between primary and secondary care. Managing heart failure requires resources across the entire spectrum of care. Strategies to prevent heart failure include both primary and secondary prevention, and should encompass risk factors control and screening strategies for cardiac dysfunction in the community. Screening for high risk patients and, at least, for patients with asymptomatic systolic dysfunction is cost effective. Therefore, to improve heart failure outcomes and halt the epidemic, this will require shared efforts from investigators, clinicians and politicians. Health care strategy with adequate funding are imperative for successfull heart failure management. RÉSUMÉ: L’insuffisance cardiaque, déjà appelée d’épidémie du XXIeme siècle, est un problème de Santé Publique partout en Europe. Malgré les immenses progrès faits dans le domaine du traitement, dans les deux dernières décennies, l’insuffisance cardiaque est parmi les maladies cardiovasculaires la seule dont l’incidence et prévalence ne cessent d’augmenter. Ses principales caractéristiques sont une mortalité très élevée -supérieure à celle de l’ensemble des cancers - et un impact économique considérable sur les Systèmes de Santé. La prise en charge des insuffisants cardiaques doit ainsi être envisagée comme une priorité absolue. Toutefois, et bien que la sévérité de la situation soit universellement reconnue, Gouvernements et Systèmes de Santé n’ont pris que très peu de mesures concrètes, visant à freiner l’épidémie qui ne cesse de croître. Nous pouvons aujourd’hui prévenir et, sinon guérir l’insuffisance cardiaque, du moins la traiter de façon à freiner la progression de la maladie, ainsi nous soyons capables de faire le diagnostique à temps. Toute attitude térapêutique présume un diagnostique précoce et complet de la situation, sans lequel nulle attitude correcte ne pourra être prise. OBJECTIFS: Nous nous proposons analyser les problèmes du diagnostique de l’insuffisance cardiaque, à la lumière des connaissances actuelles et de notre propre expérience. Parmi les objectifs de ce travail, nous avons évalué la façon d’ont l’évolution des concepts d’insuffisance et de dysfonction cardiaque a influencé la définition et les critères de diagnostique, au cours des temps, et les conséquences du manque de consensus quant à la définition et aux critères de diagnostique pour les différentes phases d’évolution de la maladie. Nous avons discuté le rôle des symptômes, signaux et examens complémentaires dans le diagnostique de l'insuffisance cardiaque et dans les stratégies de screening de la dysfonction cardíaque. Finalement nous avons discuté quelques chemins et possibles stratégies à envisager pour la prise en charge de ces malades pour que, dans un future proche, nous soyons capables de mieux les traiter, mais aussi de mieux prévenir la maladie de façon à freiner l’épidémie. MÉTHODOLOGIE: La méthodologie utilisée pour ce travail dérive directement de l’expérience acquise dans la prise en charge des malades, et de l’investigation gérée par les difficultés perçues quant au diagnostique de l’insuffisance cardiaque, au long des années. Quand de l’élaboration de l’étude EPICA née de la nécessité d’obtenir des données épidémiologiques nationales en ce qui concerne l’insuffisance cardiaque au Portugal, nous avons conçu, selon un dessin original, un protocole d’investigation qui nous a permis d’évaluer la qualité du diagnostique de l’insuffisance cardiaque réalisé par les médecins de famille ainsi que le rôle des symptômes, des signaux, des données de l´histoire clinique, de l’électrocardiogramme e de la radiographie du thorax, dans le diagnostique de l’ insuffisance dans l’ambulatoire. Nous avons aussi investigué la qualité du diagnostique établi pendant l’hospitalisation. Nous avons déterminé la réelle prévalence de l’insuffisance cardíaque hospitalisée dans notre service au long de six mois et celle qui a été codifiée au moment de la sortie de l´hôpital. Nous avons encore comparé la qualité do diagnostique avant et après l’ouverture d’une unité d’insuffisance cardiaque et la performance des différents peptides natriurétiques dans le diagnostique du syndrome. Sous la forme de réponse à un questionnaire, qui leur a été adressé par le Groupe de Travail d’insuffisance cardiaque de la Société Portugaise de Cardiologie, sur la prise en charge de l’insuffisance cardiaque, les Directeurs des Services de Cardiologie et Médicine Interne de tout le Pays se sont prononcés sur à leurs difficultés, en ce qui concerne le diagnostique et le traitement de l’insuffisance cardiaque. Les résultats des investigations partielles ont été communiqués à la communauté scientifique et publiés dans les journaux de la spécialité, au long de ces dernières années. Cette dissertation est constituée par les papiers publiés et en publication auxquels nous avons additionné une révision de l’état actuel de l’art du diagnostique de l’insuffisance cardiaque, ainsi q’une réflexion sur les 317 TESE3 AF 6/9/08 12:25 PM Page 317 318 Résumé conséquences des difficultés éprouvées au diagnostique de la maladie et sur la manière d’améliorer la prise en charge de l’insuffisance cardiaque.RÉSULTATS: En 1982, l’hors de notre début d’activité, nous avons eu très tôt la perception de la complexité de l’insuffisance cardiaque et du défi que constituait, pour les cliniciens, la prise en charge de ces malades. Nous avons participé au développement d’une classification physiopathologique originale qui a servi de base pour le doctorat de la Professeur Fátima Ceia en 1989. L’article 1 – Insuffisance cardiaque : nouveaux concepts physiopathologiques et leurs applications thérapeutiques – publié en 1984, nous décrivons déjà l’insuffisance cardiaque comme une maladie systémique, résultat de l’interaction des différents mécanismes de compensation de la dysfonction cardiaque. Nous proposons « une classification physiopathologique avec application thérapeutique » originale, où nous définissons les différents types d’insuffisance cardiaque et leurs caractéristiques cliniques, hémodynamiques, fonctionnelles et anatomiques et proposons un traitement individualisé d’accord avec la définition et le diagnostique de chacun de ces différents types d’insuffisance cardiaque. En 1994, l’article 2 – L’insuffisance cardiaque et le clinicien à la fin du XXème siècle – fait une description détaillée de comment les différents mécanismes de compensation interagissent, influencent l’évolution de la maladie, produisent les différents syndromes et justifient le choix du type de traitement. Nous discutons l’évolution de la définition de la maladie d’accord avec l’évolution de l’investigation et une meilleure connaissance de la physiopathologie de la dysfonction cardiaque. Nous soulignons la nécessité du diagnostique et du traitement précoces et quant urgent il est de développer des stratégies capables de prévenir la maladie. Les investigateurs défendent aussi l’existence d’un continu entre l’insuffisance cardiaque à fraction d’éjection normale e celle qui s’accompagne de dysfonction systolique ventriculaire. Ce concept défend l’existence de plusieurs syndromes d’insuffisance cardiaque qui ne représenteront que des phénotypes différents d’une même maladie. Des nouvelles Recommandations pour le diagnostique et exclusion de l’insuffisance cardiaque à fraction d’éjection normale / dysfonction diastolique surgissent. Nous revisitons ces nouveaux concepts dans le chapitre: L’insuffisance cardiaque: de la physiopathologie à la clinique - un modèle en constante évolution. Au chapitre II – Le diagnostique de l’insuffisance cardiaque: problèmes et conséquences prévisibles - nous analysons les conséquences du manque de critères de diagnostique consensuels pour l’insuffisance cardiaque au long de tout son spectre. Les difficultés avec le diagnostique se répercutent sur les résultats des grandes études épidémiologiques. Nous avons senti cette difficulté quand, lors de l’élaboration du programme EPICA – ÉPidémiologie de l’Insuffisance Cardiaque et Apprentissage - nous avons voulu définir les critères pour le diagnostique de l’insuffisance cardiaque de tous les types, applicables à l’ambulatoire et d’accord avec les Recommandations Internationales. L’article 3 - Épidémiologie de l’insuffisance cardiaque – analyse les conséquences des différentes définitions et critères de diagnostique utilisés dans les grandes études épidémiologiques qui, au long des années, ont publié des prévalences et incidences très variables de l’insuffisance cardiaque. Ce problème s’aggrave encore quand il s’agit de l’épidémiologie de l’insuffisance cardiaque à fraction d’éjection normale ou dysfonction diastolique, ou des stratégies pour le screening de la dysfonction cardiaque asymptomatique, situations à définitions et critères encore moins consensuels. L’inexistence de Recommandations appuyées sur l’évidence, pour le traitement de l’insufisance cardiaque à fraction d’éjection normale ou à dysfonction diastolique, est une autre des conséquences de ces difficultés. C’est ainsi que des différences de méthodologie, de définitions et de critères de diagnostique, plutôt que des différences réelles entre les populations, difficultent notre connaissance quant à la réelle surcharge que l’insuffisance cardiaque et la dysfonction cardiaque imposent au Système National de Santé. Il est ainsi difficile de prévoir les recours nécessaires, à attribuer à une situation qui est mal connue. L’ article 4 – Prévalence de l’insuffisance cardiaque au Portugal – présente le dessin des études EPICA et EPICA-RAM. EPICA a été l’une des premières études TESE3 AF 6/9/08 12:25 PM Page 318 Résumé 319 à évaluer la prévalence de l’insuffisance cardiaque symptomatique globale, de l’ambulatoire, suivant les Recommandations de la Société Européenne de Cardiologie pour le diagnostique de l’insuffisance cardiaque. Nous y définissons des critères echocardiographiques précis pour tous les types d’insuffisance cardiaque, notamment celle à fraction d’éjection normale, alors qu’à l’époque il n’y avait pas encore de Recommandations consensuelles pour le diagnostic de cette situation. L’article 5 – Prevalence of chronic heart failure in Southwestern Europe : the EPICA study - relate la prévalence de l’insuffisance cardiaque au Portugal continental en 1998. Dans une population de 5434 individus âgés de plus 25 ans, représentative de la population portugaise nous avons identifié 551 cas d’insuffisance cardiaque, correspondant à une prévalence de 4,3%, qui augmente avec l´âge, chez les deux genres ; chez 1,3% la dysfonction ventriculaire est systolique, alors que 1,75% ont une fraction d’éjection normale. L’article 6 – Epidemiology of chronic heart failure in Primary Care in the Autonomic Region of Madeira: the EPICA-RAM study – a suivi le même protocole d’investigation et relate une prévalence de l’insuffisance cardiaque globale de 4,69%, 0,76 % à dysfonction ventriculaire systolique et 2,74% à fraction d’éjection normale. Ces deux études confirment que quand le diagnostique est suspecté par la clinique il ne se confirme objectivement qu’en la moitié des cas, ce qui fait supposer que beaucoup de malades seront sous médication inappropriée pour l’insuffisance cardiaque alors que d’autres, qui auraient tout intérêt à la faire, en seront probablement privés. L’article 7 – Diagnosis of chronic heart failure in Primary Care - revoit l’état de l’art quant au diagnostique de l’insuffisance cardiaque dans la communauté et discute les principaux défis auxquels les médecins de famille sont soumis, notamment les difficultés d’accès aux examens complémentaires de diagnostique et le screening de la dysfonction cardiaque asymptomatique dans la population en général. Mais les problèmes de diagnostique de l’insuffisance cardiaque, se posent transversalement à tous les niveaux, à l’hôpital comme chez le médecin de famille. Bien que l’insuffisance cardiaque soit la première cause d’hospitalisation après les 65 ans, responsable pour la plupart des coûts consommés par le syndrome, le diagnostique y est sous-estimé. L’article 9 – Validity of a diagnosis of heart failure : implications of misdiagnosing – démontre que l’insuffisance cardiaque a été la première cause d’hospitalisation dans notre service, pendant une période de six mois, ayant une prévalence de 17% et a été largement sous codifiée. La sous codification du diagnostique ne fait que diminuer le vrai poids du syndrome, menant à l’allocation incorrecte de recours pour la prise en charge de l’insuffisance cardiaque à l´hôpital et pour l’établissement de programmes capables de faire l’indispensable interface avec l’ambulatoire. En réponse au questionnaire sur la prise en charge de l’insuffisance cardiaque, que nous résumons dans l’article 8 – Traitement de l’insuffisance cardiaque dans les hôpitaux portugais : résultats d’un questionnaire - les Directeurs des Services de Médicine Interne ont relaté leurs difficultés d’accès à l’échocardiographie en temps utile et réclamé plus de collaboration du cardiologue; les Directeurs des Services de Cardiologie demandent plus de spécialistes et de structures vocationnées pour le diagnostique et traitement de l’insuffisance cardiaque. Les difficultés posées par le diagnostique de l’insuffisance cardiaque à tous les niveaux de soins, entraînent des conséquences épidémiologiques, socioéconomiques et financières néfastes pour le patient, la planification du Système National de Santé et la Santé Publique. Au chapitre III nous rappelons l’importance du diagnostique complet de l’insuffisance cardiaque. Au diagnostique anatomique, fonctionnel et du syndrome, il faut absolument joindre l’étiologie, la classe fonctionnelle e les comorbidités qui conditionnent souvent l’interprétation des testes de diagnostique, le traitement et le pronostique. Conscients des difficultés éprouvées para les médecins de famille, pour diagnostiquer correctement et en temps utile l’insuffisance cardiaque dans l’ambulatoire, et du rôle de ces Spécialistes en ce qui concerne la contention de l’épidémie, nous nous sommes proposés, comme objectifs secondaires de l’étude EPICA,d’investiguer la performance des instruments de diagnostique disponibles et à portée de ces cliniciens. L’article 10 – The diagnosis of heart failure in primary TESE3 AF 6/9/08 12:25 PM Page 319 320 Résumé care: value of symptoms and signs – documente les limitations des symptômes, signaux et des données cliniques, quand utilisés de forme isolée, pour le diagnostique de l’insuffisance cardiaque. Ils sont tous peu sensibles et ceux qui ont la plus grande valeur prédictive sont ceux qui s’associent aux formes congestives, plus graves, de la maladie: la dyspnée paroxysmale nocturne (LR 35,5), l’orthopnée (LR 39,1), la difficulté respiratoire pendant la marche en plan horizontal (LR 25,8), l’ ingurgitation jugulaire > 6 cm accompagnée d’ hépatomégalie e d’oedème des membres inférieurs (LR 130,3), le galop ventriculaire (LR 30,0), la tachycardie >110ppm (LR 26,7) et les crépitations pulmonaires (LR 23,3) sont ainsi associés au diagnostique, mais sont très peu fréquents chez les insuffisants cardiaques tout venant de l’ambulatoire. Un traitement antérieur avec du diurétique (LR 10,6) ou de la digoxine (LR 24,9), ou encore un épisode antérieur d’oédeme pulmonaire aigu (LR 54,2), sont d’autres prédicteurs du diagnostique. L’article 11 – Aetiology, comorbidity and drug therapy of chronic heart failure in the real world: the EPICA substudy – confirme que l´hypertension artérielle est, d’entre tous les facteurs de risque, la principale étiologie de l’insuffisance cardiaque dans l’ambulatoire au Portugal (80%). Trente neuf pourcent des malades inclus dans l’étude EPICA avaient une histoire de maladie coronarienne et 15% de fibrillation auriculaire. Nous avons encore analysé la comorbidité et son influence sur la prescription, en sachant que la prescription des médicaments recommandés pour l’insuffisance cardiaque est, au Portugal comme d’une forme générale en Europe, bien inférieur au désirable. L’article 12 - The value X- ray for confirming or refuting a suspected diagnosis of heart failure in the community – démontre que les données de l’électrocardiogramme e de la radiographie du thorax, par sois même, ne prédisent pas correctement le diagnostique de l’insuffisance cardiaque dans l’ambulatoire; 25% des insuffisants cardiaques inclus dans EPICA avaient un électrocardiogramme où une radiographie du thorax normal. Al’article 13 - Evaluation of the performance and concordance of clinical questionnaires for heart failure in primary care – nous avons comparé sept questionnaires ou scores cliniques habituellement utilisés pour le diagnostique de l’insuffisance cardiaque dans les grandes études épidémiologiques et de médicaments. Ils ont démontré avoir une concordance à peine raisonnable à bonne entre eux, et être très spécifiques (>90%) pour le diagnostique mais peu sensibles. Ils augmentent la probabilité du diagnostique de 4,3% prétest vers 25 à 30% post-test et se révèlent ainsi des instruments plus utiles dans l’exclusion d’une cause cardiaque pour les symptômes que pour le diagnostique de l’insuffisance cardiaque. L’article 14 – Épidémiologie de l’insuffisance cardiaque au Portugal continental : nouvelles données de l’étude EPICA – compare les caractéristiques des malades qui, ayant une clinique compatible avec le syndrome, ont été inclus dans EPICA mais n’avaient pas de dysfonction cardiaque objective (faux positifs), avec ceux qui ont eu leur diagnostique objectivement confirmé. Les premiers étaient plus âgés, il y avait plus de femmes, plus de poids excessif, moins de maladie coronarienne. L’investigation confirme encore que les données de l’électrocardiogramme e de la radiographie du torax ne distinguent pas les insuffisants cardiaques qui ont une dysfonction systolique ventriculaire de ceux qui ont une fraction d’éjection normale. Face au défi du diagnostique de l’insuffisance cardiaque à fraction d’éjection normale, aux difficultés d’accès à l’échocardiographie dans l’ambulatoire, au prix de l’examen et aux critères encore peu consensuels pour le diagnostique de cette situation, nous avons analysé et publié à l’article 15 – The diagnostic challenge of heart failure with preserved systolic function in primary care setting: an EPICA-RAM substudy - la valeur des peptides natriurétiques du type B, NTproBNP, comme test de triage des malades qui, parmi ceux qui présentent une clinique compatible avec le syndrome, devront confirmer objectivement le diagnostique par échocardiographie. Ainsi, nous avons évalué la performance du test comme prédicteur : du diagnostique d’insuffisance cardiaque à fraction d’éjection normale, selon les Recommandations internationales, d’hypertrophie ventriculaire gauche et de dilatation de l’auricule gauche. Le NT-proBNP n’à été bon prédicteur que de ce dernier paramètre, ce qui nous fait conclure que le test ne permet pas de trier les malades de façon à diminuer les nécessités d’échocardiographie face à une hypothèse clinique d’insuffisance cardiaque, du moins en ce qui concerne les cas peu évolués, fréquemment asymptomatiques, de TESE3 AF 6/9/08 12:25 PM Page 320 Résumé 321 l’ambulatoire. Nous avons aussi comparé la performance des peptides natriurétiques du type B - BNP et NT-proBNP – quant au diagnostique de l’insuffisance cardiaque symptomatique à dysfonction ventriculaire systolique et à fraction d’éjection normale, traitée à l’hôpital. Les résultats de cette investigation sont révélés dans l’article 16 – Comparative value of BNP and NT-proBNP for the diagnosis of heart failure. Les deux tests ont démontré une performance excelente et comparable dans le diagnostique du syndrome, mais aucun n’a été capable de distinguer les deux types d’insuffisance cardiaque. Nous avons revu et discuté l’état de l’art quant au rôle des différents examens complémentaires, notamment des peptides natriurétiques et de l’échocardiographie, dans le diagnostique des différents types d’insuffisance et de dysfonction cardiaque, ainsi que les toutes dernières Recommandations internationales. Nous avons analysé les stratégies proposées pour le screening de la dysfonction ventriculaire asymptomatique, qui est au moins aussi fréquente dans l’ambulatoire que l’insuffisance cardiaque symptomatique. Par ailleurs, l’évidence montre que le traitement précoce de la dysfonction ventriculaire asymptomatique, est efficace et diminue les coûts. Le gold standard pour le screening de la dysfonction ventriculaire imposerait la réalisation d’un échocardiogramme à toute la population, ce qui est incomportable. Plusieurs stratégies ont été investiguées, ces dernières années, à la recherche de celle qui sera la plus efficace tout en épargnant le plus possible. Tous affirment que aucun examen isolé ne pourra être suffisant pour ce screening. Par contre, l’électrocardiogramme et/ou les peptides natriurétiques, incorporés ou non en scores cliniques, sont souvent évoqués comme testes efficaces pour le pré-screening des patients à envoyer à l’échocardiographie. Son utilisation diminue le nombre ’échocardiogrammes nécessaires et la dépense, tout en étant au moins aussi efficace que le screening du cancer du sein ou du colle de l’utérus, exige un investissement qui n’est en rien supérieur. Quelques auteurs ont démontré que l'exécution d’un échocardiogramme qualitatif, fait avec un échocardiographe portable, après l’ECG ou la détermination du BNP/ NT-proBNP et avant l’échocardiogramme complet, améliore encore la stratégie pour le screening de la dysfonction cardiaque. Finalement nous terminons avec quelques commentaires concernant les perspectives futures pour la prise en charge de l’insuffisanc e cardiaque. Il est absolument urgent et primordial d’établir d’une définition précise et universelle, ainsi que de critères de diagnostique objectifs, simples et reproductibles, applicables à tout le spectre de l’insuffisance cardiaque, de façon à ce que, dans un futur proche, nous soyons capables de connaître le véritable poids de l’insuffisance cardiaque, d’organiser une prise en charge le plus efficace possible tout en respectant l’inévitable contention des dépenses publiques. Les problèmes de diagnostique de l’ambulatoire exigent que les médecins de famille disposent de programmes de formation continus et que le dialogue avec l’hôpital et les spécialistes soit facilité, tel que nous l’avons fait, de forme programmée, systématiquement,pendant le programme EPICA. Les cliniques d’insuffisance cardiaque et les programmes structurés de prise en charge de l’insuffisance cardiaque ont démontré leur efficacité. Ils permettent une meilleure implémentation des Recommandations de diagnóstique et traitement, améliorent la qualité de vie et la survie des insuffisants cardiaques qui y sont suivis. Dans l’article 17 - Translating Guidelines into clinical practice : benefits of an acute heart failure unit - nous rendons compte de notre expérience en ce qui concerne les gains obtenus quant au diagnostic et traitement des insuffisants cardiaques hospitalisés dans notre service avant et après l’ouverture d’une unité d’insuffisance cardiaque et qui nous a permi d’amelliorer la qualité des soins prêtés à ces malades. Nous défendons que ces unités spécialement vocationnées pour la prise en charge de l’insuffisance cardiaque doivent se multiplier, s’intégrer en programmes plus vastes d’organisation de soins à prêter aux insuffisants cardiaques, qui incluent notamment l´hôpital de jour et adopter des structures variables d’accord avec les nécessités des populations qu’elles servent. Ces programmes de prise en charge de l’insuffisance cardiaque pourront assumer un rôle déterminant dans la formation scientifique des médecins, spécialement des médecins de famille, dans l’interface entre les soins primaires et l’hôpital et dans la référentiation des insuffisants cardiaques. Tous les efforts pour identifier et corriger précocement les facteurs de risque cardiovasculaire et développer TESE3 AF 6/9/08 12:25 PM Page 321 Résumé des stratégies pour le screening de la dysfonction cardiaque doivent être multipliés comme stratégies de prévention. Tout cela est possible, efficace à un pris semblable à celui d’autres programmes déjà en cours, mais exige la collaboration de tous, population, professionnels de santé, investigateurs et pouvoir politique qui viabilise l’évaluation des nécessités, le montage de ces programmes multidisciplinaires, et en contrôle la qualité, de façon à ce que très vite nous puissions contrôler cette épidémie.

The objective of the current study is to present the case of an intercollegiate basketball player diagnosed with an ifliopathic cardiomyopathy. The athlete illustrated in the case study experienced ongoing chest discomfort with exercise. Episodic chest pain and syncope in athletes is often alarming and may signal an underlying cardiac condition. Early recognition and maJagement of these athletes is vital to the prevention of sudden cardiac death (SCD). Fortunately, the athlete was referred to a cardiologist by her team physician during her pre-participation physical examination to rule out heart conditions that may lead to SCD. The athlete was presented a mildly reduced ejection fraction during her screening with the cardiologist. In cardiovascular physiology, ejection fraction is the fraction of end-diastolic volume that is ejected from the ventricle with each heart beat. Damage to the myocardium, as seen in cardiomyopathies, decreases the heart's ability to eject blood and therefore reduces the ejection fraction. The athlete underwent VO2max testing as well where it was discovered that her VO2max was exceptionally low for a physically active division-I athlete. This low VO2max suggested that the athlete had an insufficient oxygen uptake during intense exercise. The athlete experienced a treatment protocol consisting of a progressive conditioning regimen of additional cardiovascular exercise that proved to be effective in raising her VO2max by 10%. The athlete returned to full participation and remained asymptomatic throughout the remainder of the season. The pre-participation physical examination is crucial in early detection of events that may lead to sudden cardiac death. A thorough history and physical examination are the most efficient screening methods for detecting cardiovascular abnormalities. Any athlete with episodes of syncope, hypertension, or changes in heart rhythm should be referred to a physician.

Ventricular dysfunction and dilated cardiomyopathy (DCM) develop among untreated HIV-infected people at much higher rates than among HIV-negative individuals, resulting in significant contributions to morbidity and mortality. Mechanisms underlying development of HIV-associated cardiomyopathy (HIVCM) are as yet poorly understood. The well-characterized simian immunodeficiency virus (SIV) model of HIV infection provides a unique context for HIVCM pathogenesis studies in that SIV-infected rhesus monkeys develop myocardial lesions and contractile dysfunction similar to those described in HIV-infected people, suggesting a shared disease mechanism. Lymphocytic myocarditis is a commonly reported finding in AIDS patients at autopsy and constitutes one of several conditions known to predispose to development of DCM, irrespective of HIV-infection status. As lymphocytic myocarditis also occurs with high frequency among SIV-infected rhesus monkeys, a retrospective analysis of rhesus monkey cardiac tissue collected at necropsy was performed to examine viral and cellular correlates of lymphocytic inflammation within myocardial tissue. One subpopulation of macrophages, which has been reported by other groups to be associated with an anti-inflammatory phenotype, was found to correlate inversely with lymphocytic infiltration and positively with numbers of virus infected cells, suggesting effects of an anti-inflammatory cytokine production profile. In contrast, the detrimental effects of inflammatory cytokines on myocardial structure and function are well-recognized and HIV infection in general is characterized by chronic immune activation and inflammatory cytokine dysregulation. To further investigate a role for myocardial cytokine production in development of HIVCM, a prospective study was conducted in which SIV-infected rhesus monkeys and uninfected controls were treated with recurrent administration of inactivated Mycobacterium aviumcomplex bacteria (MAC). SIV-infected, MAC-treated animals rapidly developed significant ventricular systolic dysfunction and chamber dilatation not seen in control groups, suggesting an exaggerated myocardial sensitivity to exogenous antigenic stimulation. Concurrent treatment with the TNFα antagonist etanercept completely abrogated development of these changes, strongly implicating a causative role for TNFα in evolution of the contractile dysfunction and chamber remodeling. Findings reported from the current studies suggest that characteristics of local myocardial macrophage populations and the myocardial tissue cytokine milieu may play more important roles than lymphocytic infiltration, cardiomyocyte damage, or viral proteins in the pathogenesis of HIVCM.

Background Chronic Obstructive Pulmonary disease (COPD) is an under-diagnosed disease with a prevalence of approximately 10%, highly dependent on age and smoking habits. Comorbidities are common in COPD and of these, cardiovascular diseases (CVD) are the most common. COPD is the fourth leading cause of death globally, and CVD probably contribute to the high mortality. Within CVD, Ischemic Heart Disease (IHD) is the most common. It is highly clinically relevant to identify signs of ischemic heart disease, other cardiac conditions, and risk factors for CVD in COPD. Electrocardiogram (ECG) is a simple but still major diagnostic tool in clinical cardiology, including disturbances in the electric conduction system and ischemia. Due to the under-diagnosis of COPD, there is limited knowledge regarding the prevalence and prognostic impact of ECG abnormalities in COPD. Arterial stiffness is a risk factor for CVD, which has raised an increased interest, however not evaluated in population based studies of COPD. Aim The overall aim was to describe cardiovascular aspects on COPD, with a specific focus on arterial stiffness, prevalence and prognostic impact of ischemic ECG abnormalities and prolonged QT interval, by comparing subjects with and without obstructive lung function impairment in a population-based cohort. Methods The thesis is based on the Obstructive Lung Disease in Northern Sweden (OLIN) COPD study; a population-based longitudinal cohort study. During the years 2002-2004, all participants in clinical examinations from previously recruited large population-based cohorts were invited to re-examination including spirometry and a structured interview. All subjects with obstructive lung function impairment (n=993) were identified, together with 993 age and sex-matched referents without airway obstruction. The study population (n=1986) has been invited to annual examinations since 2005 including spirometry and structured interview. Papers I-III are based on data from 2005 when electrocardiogram (ECG) was recorded in addition to the basic program. All ECGs were Minnesota coded and QT-time was measured. Paper IV is based data from 2010 when non-invasive measurements of arterial stiffness, assessed as pulse wave velocity (PWV), was added to the program. Spirometric data were classified as normal lung function (NLF), restrictive spirometric pattern (RSP) and airway obstruction (COPD). The following spirometric criteria for COPD were used: post-bronchodilator FEV1/VC<0.70 (papers I-IV, in paper III labelled GOLD-COPD) and lower limit of normal, LLN (LLN-COPD) (paper III). Spirometric classification of COPD severity was based on FEV1 % predicted as a continuous variable or according to the Global Initiative for Obstructive Lung Disease (GOLD), divided into GOLD 1-4. Results The prevalence of ischemic heart disease (IHD), both self-reported and assessed as probable and possible ischemic ECG abnormalities (I-ECG) according to the Whitehall criteria, was similar among subjects with NLF and COPD. The prevalence of both self-reported and probable (I-ECG) according to Whitehall increased by GOLD grade.  Among those with COPD, self-reported IHD was associated with disease severity, assessed as FEV1 % predicted also after adjustment for age and sex (paper I). In both COPD and NLF, those with I-ECG had a higher cumulative mortality over 5 years than those without I-ECG (29.6 vs. 10.6%, p<0.001 and 17.1 vs. 6.3 %, p=0.001). When analysed in a multivariate model, the Mortality Risk Ratio (MRR, 95%CI) was increased for subjects with COPD and I-ECG (2.4, 1.5-3.9), and non-significantly so for NLF with I-ECG (1.65, 0.94-2.90), when compared to NLF without I-ECG.  When analyzed separately among subjects with COPD, the increased risk for death associated with I-ECG persisted independent of age, sex, BMI-class, smoking habits and disease severity assessed as FEV1 % predicted (1.89, 1.20-2.99). The proportion without reported IHD was high among those with I-ECG; 72.4% in NLF and 67.3% in COPD. The pattern was similar also among them; I-ECG was associated with an increased risk for death in COPD and non-significantly so in NLF (paper II). Mean corrected QT-time (QTc) and prevalence of QTc prolongation was higher in RSP than NLF but similar in NLF and GOLD-COPD. The prevalence of borderline as well as prolonged QTc increased by GOLD grade (test for trend p=0.012 for both groups). Of those with GOLD-COPD, 52% fulfilled the LLN-criterion (LLN-COPD). When comparing LLN-COPD and NLF, the pattern was similar as when comparing NLF and GOLD-COPD. The cumulative mortality over 5 years was higher among subjects with borderline and prolonged QTc than those with normal QTc in subjects with GOLD-COPD and LLN-COPD but not in NLF and RSP (paper III). Arterial stiffness, assessed as PWV, was higher in GOLD 3-4 compared to non-COPD (10.52 vs. 9.13 m/s, p=0.042). Reported CVD and age >60 were both associated with significantly higher PWV in COPD as well as in non-COPD. In a multivariate model, GOLD 3-4 remained associated with higher PWV when compared with non-COPD, also when adjusted for sex, age group, smoking habits, blood pressure, reported CVD and pulse rate (paper IV). Conclusion In this population-based study, the prevalence of ischemic ECG abnormalities was similar among subjects with normal lung function and COPD, but increased by disease severity among subjects with COPD. Ischemic ECG abnormalities were associated with an increased mortality among subjects with COPD, independent of common confounders and disease severity, also among those without known heart disease. Whilst the prevalence of QTc prolongation was similar in NLF, COPD and LLN-COPD, it was associated with an increased mortality only in the COPD-groups. ECG is a simple non-invasive method and seems to identify findings of prognostic importance among subjects with COPD. Central arterial stiffness, a known risk factor for cardiovascular disease, was increased among subjects with severe and very severe COPD when compared to subjects without COPD independent of common confounders.

FundaÃÃo Cearense de Apoio ao Desenvolvimento Cientifico e TecnolÃgico
CoordenaÃÃo de AperfeiÃoamento de Pessoal de NÃvel Superior
Over the past few years, there has been increasing evidence of the effect of the oral health over the general health of individuals, supported by a series of biological and epidemiological studies that show a relation between the mouth and many diseases, including cardiovascular diseases. Structural deficiencies and functional abnormalities of heart valves represent an important cause of cardiovascular morbidity and mortality in Brazil, and a few defects have been recently associated with infectious agents. The aim of this study was to identify cariogenic and periodontopathogenic bacteria in dental plaque, saliva and heart valves, without clinical endocarditis, of patients with heart valve diseases, and correlate these findings with the oral health status of the patients. Oral exams using the DMTF (decayed, missing and filled teeth) and PSR (Periodontal Screening and Recording) indexes to evaluate caries and periodontal disease, respectively, were performed. Samples of supragingival and subgingival dental plaque, saliva and cardiac valves were evaluated, through Real Time Polymerase Chain Reaction, for the presence of DNA of Streptococcus mutans (S. mutans), Prevotella intermedia (P. intermedia), Porphyromonas gingivalis (P. gingivalis) and Treponema denticola (T. denticola). A total of 114 samples were collected from 42 patients with a mean age of 55.6 Â 13.8 years. The average number of missing teeth due to caries was 23.52 Â 9.41 teeth per patient, and according to the highest score of periodontal disease observed for each patient, excluding edentulous patients (44.0%), periodontal pockets over 4mm (43.4%) and dental calculus (34.7%) were detected in a higher number of patients. The molecular analysis of the oral samples revealed high frequency of S. mutans and P. intermedia in supragingival dental plaques, subgingival dental plaques and saliva of dentate and edentulous patients (variation 60.0% - 100.0%), while P. gingivalis and T. denticola were detected in a smaller number of oral samples (variation 17.6% - 64.0%). The microorganism most frequently detected in heart valve samples was the S. mutans (89.3%), followed by P. intermedia (19.1%), P. gingivalis (4.2%) e T. denticola (2.1%). Significant difference was observed between the frequency of P. intermedia, P. gingivalis and T. denticola in the heart valve and dental plaque, as oposed to S. mutans. The identification of oral bacteria, especially S. mutans, in heart valves of patients with a previous history of dental caries and gingivitis/periodontitis suggests the possible involvement of these pathogens in the etiopathogenesis of heart valve diseases.
Atualmente, cada vez mais se tem evidÃncias do efeito da condiÃÃo oral na saÃde geral dos indivÃduos, atravÃs de uma sÃrie de estudos epidemiolÃgicos e biolÃgicos que mostram uma relaÃÃo entre a boca e diversas doenÃas, incluindo as doenÃas cardiovasculares. Desordens estruturais e nas funÃÃes das vÃlvulas cardÃacas representam uma importante causa de morbidade e mortalidade cardiovascular no Brasil, sendo alguns processos, como a estenose aÃrtica degenerativa, mais recentemente associados a agentes infecciosos. O objetivo desta pesquisa foi identificar bactÃrias cariogÃnicas e periodontopatogÃnicas na placa dental, saliva e vÃlvulas cardÃacas, sem endocardite clÃnica, de pacientes com doenÃa valvar, correlacionando esses achados à condiÃÃo bucal dos indivÃduos. AvaliaÃÃo, quanto Ãs doenÃas cÃrie e periodontal, foi realizada, atravÃs dos Ãndices CPO-D (Dentes Permanentes Cariados, Perdidos e Obturados) e PSR (Registro Periodontal Simplificado), respectivamente. Amostras de placa dental supragengival, subgengival, saliva e vÃlvula cardÃaca foram coletadas para investigaÃÃo da presenÃa de DNA, atravÃs de PCR (ReaÃÃo em Cadeia de Polimerase) em tempo real, de Streptococcus mutans (S. mutans), Prevotella intermedia (P. intermedia), Porphyromonas gingivalis (P. gingivalis) e Treponema denticola (T. denticola). Um total de 114 amostras foi coletado de 42 pacientes com mÃdia de idade de 55.6  13.8 anos. A mÃdia de dentes perdidos devido à cÃrie, por paciente, foi em torno de 23.52  9.41 e, segundo o maior grau de doenÃa periodontal observado no indivÃduo, excluindo-se os pacientes desdentados totais (44.0%), bolsa superior a 4 mm (43.4%) e o cÃlculo dental (34.7%) esteve presente em um maior nÃmero de pacientes. A anÃlise molecular das amostras bucais revelou alta frequÃncia de S. mutans e P. intermedia nas placas supragengival, subgengival e saliva de pacientes dentados e desdentados (variando entre 60.0% e 100.0%), enquanto que P. gingivalis e T. denticola estiveram presentes em menor nÃmero de amostras bucais (variando entre 17.6% e 64.0%). O micro-organismo mais frequentemente encontrado nas amostras valvares foi o S. mutans (89.3%), seguido da P. intermedia (19.1%), P. gingivalis (4.2%) e T. denticola (2.1%). DiferenÃa significativa foi encontrada entre a presenÃa de P. intermedia, P. gingivalis e T. denticola na vÃlvula e na placa dental, diferentemente do S. mutans. A identificaÃÃo de bactÃrias orais, principalmente S. mutans, em vÃlvulas cardÃacas de pacientes com elevada experiÃncia prÃvia de cÃrie e ocorrÃncia de gengivite/periodontite, sugere o possÃvel envolvimento desses patÃgenos nas doenÃas valvares.

The dependence of cardiac output measurement precision on ambient temperature and cardiac output stability was assessed by concurrent continuous and bolus thermodilution methods in postoperative cardiac surgery patients. The degree of agreement between the two methods was depended on room temperature (0.1 L/min for each degree below 25 degrees C). The agreement was also closer in trials where cardiac output was stable (< 10% variation). The continuous thermodilution method shows sufficient agreement with the bolus method for use in critical care; however, improved precision of cardiac output thermodilution measurements can be achieved by use of correction factors for cardiac instability and for ambient temperature.

Hypoxia inducible factor-1α (HIF-1α) plays a critical role in the oxygen homeostasis of all metazoans. HIF-1α is a master transcriptional regulator which coordinates the adaptive response to low oxygen tension. Through activation of a plethora of downstream target genes, HIF-1α facilitates oxygenation by promoting angiogenesis and blood vessel dilation, in addition to modulating metabolic pathways to inhibit oxidative phosphorylation and promote glycolytic energy production. Given the critical roles of hypoxia, insufficient blood supply and perturbed energetics in the pathogenesis of cardiovascular disorders, notably ischaemic heart disease, therapeutic modulation of HIF-1α is of significant clinical interest. Previous studies have demonstrated an acute cardioprotective role for both endogenous and supraphysiological HIF-1α signalling in the context of myocardial ischaemia. In contrast, chronic supraphysiological HIF-1α activation in the unstressed heart has been shown to induce cardiac dysfunction. To address the effect of chronic endogenous HIF-1α activation post-myocardial infarction (MI), the present work employed a murine coronary artery ligation (CAL) model in conjunction with temporally-inducible, cardiac-specific deletion of Hif-1α. While CAL surgery successfully modelled myocardial infarction – eliciting substantial adverse cardiac remodelling and contractile dysfunction – there was no evidence of chronic HIF-1α activation by CAL in HIF knockout or control left ventricular samples. In keeping with this, chronic ablation of Hif-1α (from 2 weeks post-CAL) had no discernible additional effect upon cardiac function. Overall, these findings do not support a potential therapeutic role for inhibition of HIF-1α signalling in the chronic phase post-MI. The fundamental tricarboxylic acid (TCA) cycle enzyme fumarate hydratase (FH) converts fumarate to malate. FH deficiency is associated with smooth muscle and kidney tumours which exhibit normoxic HIF signalling due to fumarate accumulation. To investigate the potential for fumarate accumulation to elicit protective HIF signalling, a cardiac-specific Fh1 null mouse was developed through Cre-loxP recombination. Strikingly, despite interruption of the TCA cycle in a highly metabolically demanding organ, cardiac Fh1 null mice were viable, fertile and survived into adulthood, demonstrating the remarkable metabolic plasticity of the heart. However, by 3-4 months Fh1 null mice develop a lethal cardiomyopathy characterised by cardiac hypertrophy, ventricular dilatation and contractile dysfunction. Despite lack of a pseudohypoxic response, Fh1 null hearts did exhibit another phenomenon observed in FH-deficient cancers and also attributed to fumarate accumulation – activation of the nuclear factor (erythroid-derived 2)-like 2 (NRF2) antioxidant pathway. Heterozygous, but not homozygous, somatic deletion of Nrf2 extended the life expectancy of cardiac Fh1 null mice. Exploration of redox status revealed a more reductive environment in Fh1 null hearts than controls. As a corollary, inhibition of the rate limiting enzyme of the pentose phosphate pathway – a major source of cellular reducing equivalents – with dehydroepiandrosterone conferred striking amelioration of the Fh1 null cardiomyopathy, suggesting a possible pathogenic role for reductive stress. While loss of mitochondrial Fh1 activity and subsequent TCA cycle dysfunction likely contribute to the Fh1 null phenotype, the importance of cytosolic FH was unclear. To clarify this, FH was expressed specifically in the cytosol in vivo. This was sufficient to substantially rescue the Fh1 null cardiomyopathy, supporting a role for cytosolic FH disruption in its pathogenesis. Taken together, these findings highlight the potential for reductive stress to contribute to cardiac dysfunction and suggest a function for cytosolic FH in cardiac metabolic homeostasis.

Cardiovascular magnetic resonance imaging (MRI) is a well established technique in clinical cardiology. Different MRI sequences are routinely used to assess cardiac anatomy, function, viability and other parameters that aid diagnosing cardiac disease. Conversely, cardiac magnetic resonance spectroscopy (MRS), the only available method for a non-invasive study of human cardiac metabolism, has not evolved into a clinical tool yet. The combination of both techniques holds great potential to gain insight into the causality of cardiomyopathy diseases or other medical conditions with high cardiovascular risk profile, like diabetes or obesity and improve the clinical management of cardiac diseases. Nowadays, high field clinical MR systems have the great potential of improving the low spatial and temporal resolution and reproducibility of MRS. The aim of this thesis was to develop and implement a cardiac 1H-MRS method at 3 T that can be applied in clinical routine for the assessment of creatine and lipid levels in the human myocardium. The methodological developments to advance cardiac MRS are presented first. A robust 1H-MRS method comprising an optimized single-voxel technique, phased-array coil combination routine, optimized water suppression, breath-hold averaging and post-processing methods were developed. First, reproducibility and feasibility of the method were validated in vivo by acquiring 1H-MRS of the liver in almost one hundred healthy subjects. Subsequently, myocardial lipids levels were obtained in healthy volunteers by single breath-hold 1H-MRS triggered to mid-diastole, showing good reproducibility in an acquisition time less than 12 s. The good spectral resolution achieved using this method was demonstrated by the ability to differentiate for the first time two pools of myocardial lipids in spectra from the septum of patients with suspected myocardial lipid excess. Finally, creatine levels for healthy volunteers were investigated using multiple breath-hold acquisitions. Thus, this study shows the practicality and feasibility to incorporate this rapid cardiac 1H-MRS method into clinical studies of the human myocardium.

Cardiac stem cells (CSCs), isolated from heart tissue explants and expanded via the formation of cardiospheres (Csp), are a promising candidate for cell therapy to prevent heart failure following myocardial infarction. To allow early administration to patients, isolation and expansion of CSCs must be performed in the shortest time possible. Hence, this project aimed to optimize culture conditions and characterize the cardiac explant-derived cells (EDCs), Csp and Csp-derived cells (CDCs) produced. Rat neonatal EDCs contained 4-7% c-kit⁺ cells, measured using flow cytometry. Optimal Csp growth conditions were determined, such that plating 3 x 10^4 EDCs per well of a 24-well plate coated with 16.7 µg/ml poly-D-lysine, in CGM containing 7% serum, improved Csp production and generated 1.5 x 10^7 CDCs in 16 days, a sufficient number for cell therapy. The CDCs expressed the stemness markers; c-kit, Oct3/4, SOX2, and Klf-4, and the cardiac differentiation markers; GATA4 and Nkx2.5. The therapeutic effect of CDCs may be limited by the low, 3 ± 0.1%, c-kit⁺ cell numbers. To increase c-kit⁺ cells in CDCs, an alternate culture method for Csp and different extracellular matrices (ECM) for cell expansion were tested. The hanging drop culture method produced Csp with higher levels of c-kit⁺ cells (9 ± 2%) than poly-D-lysine-coated and low-bind culture dishes. Of five ECM tested, collagen IV was found to enhance EDC migration and CDC proliferation, and produced 11 ± 0.4% c-kit⁺ cells, with Csp cultured in hanging drops. Intramyocardial injection of CDCs improved left ventricular ejection fractions of infarcted rat hearts by 9% and prevented the peri-infarct wall from thinning, measured in vivo using MRI over 16 weeks. To improve cell tracking using MRI, two MR positive contrast agents, gadolinium-DTPA and gadonanotubes were tested. Gd-DTPA had low sensitivity after labelling (1.4 x 10^5 cells/mm2); whereas gadonanotubes did not provide positive contrast at 11.7 T. Thus, neither contrast agent could be used for cell tracking using high magnetic field. In conclusion, CDCs were an effective source of stem cells that could be used for heart repair, although cells could not be tracked using positive MR contrast.

Interleukin-18 (IL-18) is a pro-inflammatory cytokine known to be involved in maintaining metabolic homeostasis; however, also capable of inducing cardiac dysfunction. Additionally, IL-18, has been shown to bind to a novel receptor, the Na-Cl Co-transporter (NCC). We hypothesized that NCC mediates IL-18 metabolic and cardiac signaling in mice. Using male C57BL/6J mice, we compared the metabolic and cardiac function changes after at least 8 weeks of high-saturated fat high sugar diet (Western Diet) in NCC knockout (NCCKO), IL-18 knockout (IL-18KO), and wild-type mice. We show that NCCKO mice have significantly increased body weight gain from baseline, no difference in fasting blood glucose, and attenuated cardiac diastolic dysfunction after WD compared to wild-type mice. Collectively, the metabolic and cardiac phenotypes of NCCKO mice resembled that of the IL-18KO mice, indicating that NCC may mediate IL-18 signaling in a mouse model of diet-induced obesity and cardiac dysfunction.

Objectives: Contemporary data are lacking with respect to the incidence rates of, factors associated with, and impact of cardiac arrest from ventricular fibrillation or tachycardia (VF-CA) on hospital survival in patients admitted with an acute coronary syndrome (ACS). The objectives of this multinational study were to characterize trends in the magnitude of in-hospital VF-CA complicating an ACS and describe its impact over time on hospital prognosis. Methods: The study population consisted of 59,161 patients enrolled in the Global Registry of Acute Coronary Events Study between 2000 and 2007. Overall, 3,618 patients (6.2%) developed VF-CA during their hospitalization for an ACS. Incidence rates of VF-CA declined over time, albeit in an inconsistent manner. Patients who experienced VF-CA were on average older and had a greater burden of cardiovascular disease, yet were less likely to receive evidence-based cardiac therapies than patients in whom VF-CA did not occur. Hospital death rates were 55.3% and 1.5% in patients with and without VF-CA, respectively. There was a greater than 50% decline in the hospital death rates associated with VF-CA during the years under study. Patients with a VF-CA occurring after 48 hours were at especially high risk for dying during hospitalization (82.8%). Conclusions: Despite reductions in the magnitude of, and short-term mortality from, VF-CA between 2000 and 2007, VF-CA continues to exert a significant adverse effect on survival among patients hospitalized with an ACS. Opportunities exist to improve the identification and treatment of ACS patients at risk for VF-CA to reduce the incidence of, and mortality from, this serious arrhythmic disturbance.

Sudden cardiac death following cardiac arrest is a major killer in the industrialised world. The leading cause of sudden cardiac death are disturbances in the normal electrical activation of cardiac tissue, known as cardiac arrhythmia, which severely compromise the ability of the heart to fulfill the body's demand of oxygen. Ventricular fibrillation (VF) is the most deadly form of cardiac arrhythmia. Furthermore, electrical defibrillation through the application of strong electric shocks to the heart is the only effective therapy against VF. Over the past decades, a large body of research has dealt with the study of the mechanisms underpinning the success or failure of defibrillation shocks. The main mechanism of shock failure involves shocks terminating VF but leaving the appropriate electrical substrate for new VF episodes to rapidly follow (i.e. shock-induced arrhythmogenesis). A large number of models have been developed for the in silico study of shock-induced arrhythmogenesis, ranging from single cell models to three-dimensional ventricular models of small mammalian species. However, no extrapolation of the results obtained in the aforementioned studies has been done in human models of ventricular electrophysiology. The main reason is the large computational requirements associated with the solution of the bidomain equations of cardiac electrophysiology over large anatomically-accurate geometrical models including representation of fibre orientation and transmembrane kinetics. In this Thesis we develop simulation technology for the study of cardiac defibrillation in the human heart in the framework of the open source simulation environment Chaste. The advances include the development of novel computational and numerical techniques for the solution of the bidomain equations in large-scale high performance computing resources. More specifically, we have considered the implementation of effective domain decomposition, the development of new numerical techniques for the reduction of communication in Chaste's finite element method (FEM) solver, and the development of mesh-independent preconditioners for the solution of the linear system arising from the FEM discretisation of the bidomain equations. The developments presented in this Thesis have brought Chaste to the level of performance and functionality required to perform bidomain simulations with large three-dimensional cardiac geometries made of tens of millions of nodes and including accurate representation of fibre orientation and membrane kinetics. This advances have enabled the in silico study of shock-induced arrhythmogenesis for the first time in the human heart, therefore bridging an important gap in the field of cardiac defibrillation research.

Sepsis is the most frequent cause of mortality in most intensive care units. Cardiovascular dysfunction is a major complication associated with sepsis, with high mortality rates up to 70%. Currently, there is no effective treatment approach for sepsis. The integrity of the endothelium is fundamental for the homeostasis of the cardiovascular system. Sepsis induces endothelial cell injury which is the key factor for multiple organ failure. The increased expression of adhesion molecules and chemokines in endothelial cell promotes leukocytes infiltration into the tissue. The loss of tight junction proteins and increased permeability of the endothelial cells will provoke tissue hypoxia and subsequent organ failure. Therefore, preservation of endothelial function is a critical approach for improving sepsis-induced outcome. Here, we showed that endothelial specific protein HSPA12B plays a critical role in the preservation of cardiovascular function in polymicrobial sepsis. HSPA12B is the newest member of HSP70 family which predominantly expresses in endothelial cells. We observed that HSPA12B deficiency (HSPA12B-/-) exaggerated polymicrobial sepsis-induced endothelial dysfunction, leading to worse cardiac dysfunction. HSPA12B-/- significantly increases the expression of adhesion molecules, decreases tight junction protein levels and enhances vascular permeability. HSPA12B-/- alsomarkedly promotes the infiltration of inflammatory cells into the myocardium and inflammatory cytokine production. We investigated the cardioprotective mechanisms of HSPA12B in sepsis induced cardiovascular dysfunction. Exosomes play a critical role in intercellular communication. Exosome is a natural vehicle of microRNAs. We found that exosomes isolated from HSPA12B-/- septic mice induced more expression of adhesion molecules in endothelial cells and inflammation in macrophages. Interestingly, the levels of miR-126 in serum exosomes isolated from HSPA12B-/- septic mice were significantly lowers than in WT septic mice. Importantly, delivery of miR-126 carried exosomes significantly improved cardiac function, suppressed the expression of adhesion molecules, reduced immune cell infiltration in the myocardium, and improved vascular permeability in HSPA12B-/- septic mice. The data suggests that HSPA12B is essential for endothelial function in sepsis and that miR-126 containing exosomes plays a critical role in cardiovascular-protective mechanisms of endothelial HSPA12B in polymicrobial sepsis.

Altered glucose metabolism is the underlying factor in many metabolic disorders, including diabetes. A novel protein recently linked to diabetes through animal and clinical studies is Sarcolemmal Membrane Associated Protein (SLMAP) but its role in metabolism remains undefined. The data here reveals a novel role for SLMAP isoform1 in glucose metabolism within the myocardium. Neonatal cardiomyocytes (NCMs) harvested from hearts of transgenic mice expressing SLMAP1, presented with increased glucose uptake, glycolytic rate, as well as glucose transporter 4 (GLUT4) expressions with minimal impact on lipid metabolism. SLMAP1 expression markedly increased the machinery required for endosomal trafficking of GLUT4 to the membrane within NCMs, accounting for the observed effects on glucose metabolism. The data here indicates SLMAP1 as a unique regulator of glucose metabolism through endosomal regulation of GLUT4 trafficking and suggests it may uniquely serve as a target to limit cardiovascular disease in metabolic disorders such as diabetes.

Thesis submitted in fulfilment of the requirement for the degree Doctor of Technologiae (Biomedical Technology) in the Faculty of Health and Wellness Sciences at the Cape Peninsula University of Technology Supervisor: Prof J van Rooyen Co-supervisor: Prof JL Marnewick Bellville October 2013
Cardiovascular disease (CVD) is without a doubt one of the most challenging health issues of our time and accounts for the highest number of deaths in both developed and developing countries. Despite the huge strides that have been achieved in the diagnosis and therapeutic intervention of CVD, the disease burden still remains enormous. Therefore, this calls for novel and innovative interventions to curb the surge of CVD. The use of plant based food with bioactive phytochemicals,has a great potential to reduce the incidence of CVD, specifically in resource-strained countries. Red palm oil (RPO) and the indigenous herbal tea, rooibos have previously been shown to exhibit potential cardioprotective effects. Their health promoting properties have largely been attributed to their antioxidant and anti-inflammatory activities and emerging evidence also showed that they have the potential to modulate cell signalling events. Substancial scientific evidence proposes oxidative stress and inflammation to play an important role in the pathogenesis of cardiovascular disease. Hence, natural plant extracts such as RPO and rooibos could be recommended as adjuvants to clinical therapy to reduce the morbidity and mortality associated with CVD. This thesis reports on three studies investigating the cardiovascular protective effects that chronic feeding of either RPO, rooibos or their combination have on 1) antioxidant enzymes and the NO-cGMP pathway in myocardial tissue of spontaneous hypertensive rats, 2) the modulation of systemic and myocardial inflammation and 3) the myocardial ischaemic/reperfusion tolerance in a rat model of lypopolysaccharide induced inflammation. The aim of the first study was to investigate the effect of RPO on cardiac function in sponteneously hypertensive rats. The role of the nitric oxide cyclic-guanosine monophosphate(NO-cGMP) pathway, (as determined by the nitric oxide (NOS) activity) and the antioxidant defence system (selected antioxidant enzymes) were also investigated. Cardiac function was monitored at stabilization and reperfusion using the Langendorff perfusion system. Antioxidant enzymes were determined from left ventricular tissue, while total NOS activity was determined in the aorta and left ventricular tissue. The results show that RPO offered cardiac protection as evidenced by improved left ventricular developed pressure (LVDevP), maximum velocity of pressure rise (+dp/dt) max and fall (-dp/dt) max during reperfusion in sponteneously hypertensive rats (SHR) compared to their control counterparts. Improved function in SHR was associated with increased myocardial superoxide dismutase 2 (SOD2) protein expression compared to the normotensive rats. There was differential modulation of the NOS activity by RPO, an increase in NOS activity was observed in the aorta while a reduction in the activity of NOS was observed in the left ventricular tissue of both RPO supplemented normotensive and hypertensive rats compared to their respective control groups. These results argue a role for elevated NO production in the aorta for endothelial function maintenance. Increased SOD2 protein might lead to reduced oxidative stress. Thus, NO-cGMP pathway and antioxidant defense systems synergistically acted to restore cardiovascular function in SHR. The aim of the second study was to investigate the effect of RPO and rooibos supplementation on the modulation of systemic and myocardial inflammation in a rat model. As RPO and rooibos contain different types of antioxidants which reside and exert their biological effects in different cellular compartments, the combination of these two natural food compounds has the potential to enhance the spectrum of available dietary antioxidants in different cellular compartments, which could result in a better protection against certain pathological conditions such as inflammation. The Langendorff system and the lypopolysaccharide (LPS)-induced inflammatory model were used to determine if RPO and rooibos could protect against the negative effect of LPS-induced inflammation on baseline cardiac function. Both inflammation and dietary supplementation did not have any effect on baseline cardiac functional parameters. Our results show that administration of LPS resulted in elevated plasma levels of IL-1β in supplemented and non-supplemented rats indicating that an inflammatory response was triggered in the LPS-treated rats. However, this increase in IL-1β was counteracted by concurrent elevation of plasma IL-10 in LPS-induced rats consuming either rooibos or RPO alone. Furthermore the combination of RPO and rooibos enhanced myocardial IL-10 levels in LPS-induced rats. This data shows a difference in response to LPS injection between the myocardium and the systemic circulation. The results indicate that the combination of these two natural food substances exhibit potential anti-inflammatory properties which could be beneficial in clinically relevant conditions where inflammation plays a role. Having shown that dietary intervention with RPO and rooibos had the potential to modulate the inflammatory response in the model of inflammation at basal conditions, we then proceeded to the third study to specifically establish if dietary RPO when supplemented alone will improve functional recovery and reduce infarct size in LPS-treated hearts. The Langendorff perfusion system was employed for determination of cardiac function and infarct size. The roles of NFkB, p38 MAPK and the myocardial antioxidant defence systems were investigated as potential mechanisms of protection. LPS-treatment caused significant increases in myocardial IL-1 β indicating that inflammation was induced. However, the levels of myocardial IL-10 was reduced in LPS-treated hearts compared to the non-treated hearts. Intervention with dietary RPO resulted in improved functional recovery and reduced infarct size, in both healthy hearts and in the LPS-treatment group. The RPO-induced cardio-protection was associated with increases in myocardial protein expression of the antioxidant enzymes, SOD1, SOD2, GPX1 as well as increased p38 phosphorylation during reperfusion. LPS treatment increased myocardial protein expression of NFkB p65 which was reversed by RPO supplementation. Reduction of myocardial NFkB protein expression, increased p38 phosphorylation and elevated mitochondrial antioxidant (SOD2 and GPX1) as well as cytosolic enzymes (SOD 1) are proposed as potential mechanisms underlying the RPO-induced cardio-protection in this model. Based on these study results, for the first time, having included vasculature aspects in the cardio-protective effects of RPO we have shown that the NO-cGMP pathway and antioxidant defense systems may act synergistically to restore cardiovascular function in spontaneously hypertensive rats. Results from the second study also provide the first scientific evidence that RPO in combination with rooibos (a flavonoid rich endemic herbal tea) could have potential anti-inflammatory activities at systemic as well as myocardial level, which may be beneficial in clinically relevant conditions where inflammation plays a role. From the third study it can be concluded that dietary RPO improved myocardial tolerance to ischaemia-reperfusion injury in a model of inflammation.

Il presente lavoro di tesi è stato condotto in ambito psicocardiologico, e riguarda l’indagine delle determinanti psicosociali potenzialmente coinvolte nell’eziopatogenesi, digressione e prognosi delle malattie cardiache. Più studi preliminari sono stati condotti a fini esplorativi, e solo le varabili risultate caratteristiche del campione mantenute in indagini successive. Dopo aver indagato il ruolo del benessere psicologico nell’influenzare la Capacità Funzionale dei pazienti, uno degli indicatori di esito di maggiore importanza in Riabilitazione Cardiologica (RC) (studio 1), si è proceduto a verificare quali tra le variabili cognitive e psicologiche tradizionalmente associate alle malattie cardiache caratterizzasse lo specifico campione, condizionandone Qualità della Vita (QdV) e benessere psicologico (studio 2). Esclusa l’influenza delle variabili cognitive sullo stato emotivo dei soggetti, si è, poi, approfondito il ruolo delle variabili psicologiche nel determinarne la QdV percepita dei degenti (studio 3). Obiettivo del quarto studio è, infine, valutare efficacia ed efficienza dell’aggiunta di tecniche e principi propri del Colloquio Motivazionale (CM) al trattamento psicologico standard (Terapia Breve Strategica, TBS), al di la del solo trattamento breve strategico, nell’incrementare autoefficacia percepita, disponibilità al cambiamento ed aderenza al trattamento riabilitativo nel malati di cuore. Un esempio dell’uso di tale stile comunicativo viene, inoltre, proposto mediante caso clinico (studio 5).
The general aim of this thesis is to seek evidence on how to achieve long-term maintenance of lifestyle changes in a sample of obese inpatients with heart diseases referred to Cardiac Rehabilitation by investigating the influence of selected variables on their physical and psychological status, as well as by examining the efficacy and effectiveness of a motivational-based intervention. Study 1 is aimed at evaluating whether psychological well-being represents an independent predictor of Exercise Capacity. Study 2 focuses on investigating the influence of cognitive abilities and established psychosocial risk factors on the sample’s subjective Quality of life (QoL) and well-being. Since no effect of different levels of cognitive impairments on the expression of psychological distress among the study participants has been identified, in study 3 the effect of emotional impairments on QoL has been further explored. To conclude, the MOTIV-HEART study (study 4) is aimed at testing the incremental efficacy of a brief strategic treatment including motivational components (BST + MI) in improving physical and psychological outcomes over and beyond the stand-alone brief strategic treatment (BST) and whether results will be maintained/increased at 3-month follow-up. An example of this style of communication is also presented through a case study (study 5).

Aortic stenosis is the commonest valve disorder in the Western World. The natural history of the disease is very well described; with a decreased survival once symptoms occur. There is currently, no medical therapy available to reduce the natural progression of the aortic stenosis, and therefore, aortic valve replacement has been recognised as the standard of care treatment for symptomatic aortic stenosis, with TAVI having merged as alternative for those cases with high/prohibitive surgical risk. All types of aortic stenosis have in common a reduced valve area (AVA <1.0cm2), but depending on the mean gradients and the stroke volume index, there are different types: Normal-Flow High-Gradient (NFHG AS) and Low-Flow Low-Gradient (LFLG AS) aortic stenosis. The latter is further subdivided into Classical and Paradoxical forms depending on the ejection fraction value. NFHG AS is the most common type. The left ventricle is capable of generating a normal flow through the stenotic valve, that it is translated onto high gradients. This type has been thoroughly studied and has an excellent prognostic with aortic valve replacement, with very low in-hospital mortality and long-term survival similar to the age-matched population. LFLG AS, on the other hand, is defined by a reduced stroke volume (SVi < 35 ml/min) and a low gradient (mean gradient < 40mmHg). The Classical form (CLFLG AS) has impaired ventricular function. These patients have dilated ventricles that are not able to generate enough flow through the stenotic valve and hence the low gradient. Dobutamine stress echocardiography is key for the diagnosis of this subtype, as it differentiates it from the Pseudo-Severe aortic stenosis (in which the problem is not in the aortic valve but in the left ventricle, and therefore there is no benefit from aortic valve replacement) and it has also prognostic value by determining the contractile reserve. These patients have been reported to have the highest mortality post aortic valve replacement and a reduced long-term survival; however, those who survive achieve excellent functional class. The other subtype of LFLG, the Paradoxical form (PLFLG AS) has a preserved ventricular function. These patients have a ventricular restrictive physiology, with reduced SVi due to a combination of mechanism such as subendocardial fibrosis, concentric remodeling, impaired diastolic filling and high afterload. It is paramount here to confirm the diagnosis by accurate echocardiography, ruling out measurement errors and other causes of reduced SVi. PLFLG AS patients have worse prognosis than NFHG AS but better prognosis than CLFLG AS patients. The primary hypothesis of our research project was that aortic valve replacement could be performed in patients with LFLG AS with low in-hospital mortality. Therefore, with the objectives of determining operative and mid-term outcomes of surgical intervention in LFLG AS compared to NFHG AS, we conducted a retrospective analysis of all patients who underwent isolated aortic valve replacement in our centre. Primary end-points were mortality (in-hospital, at one and five years) and the secondary end-points analysed were postoperative complications and clinical status at follow-up. Patients in the LFLG AS group were significantly older and had more cardiovascular risk factors and comorbidities than the NFHG AS group. Despite those differences, in-hospital mortality was equivalent and remarkably low in both groups. As expected, LFLG AS patients had a reduced mid-term survival but those who survived remained in an excellent functional class. With the separate analysis of the LFLG AS subgroups, we confirmed that CLFLG AS had higher in-hospital and mid-term mortality than PLFLG AS patients. In both groups, the in-hospital mortality was remarkably low compared to previous literature reports. Aortic valve replacement provided symptomatic relief and excellent functional class during the mid-term follow-up as well as recovery of the ventricular function in most of the patients. Based on our results, we concluded that aortic valve replacement should be recommended for symptomatic severe LFLG AS.
La estenosis aórtica es la enfermedad valvular más frecuente en el tercer mundo. La historia natural de la enfermedad es bien conocida desde hace décadas, siendo una enfermedad con mal pronóstico a medio-corto plazo que hace necesario someter a estos pacientes a recambio valvular aórtico tras la aparición de síntomas. La forma mas común de estenosis aórtica, con flujo normal y gradiente alto, tiene un pronóstico excelente tras el recambio valvular aórtico, con una supervivencia similar a la de la población normal. Sin embargo, la estenosis aórtica de bajo-flujo y bajo-gradiente, es una entidad menos conocida y de peor pronóstico. Estos pacientes tienen una mortalidad mucho mayor tras recambio valvular aórtico y menor supervivencia a largo plazo. El diagnóstico en el bajo-flujo bajo-gradiente es vital para seleccionar correctamente los pacientes con estenosis aórtica que se beneficiarán de tratamiento quirúrgico, teniendo también valor pronóstico, dependiendo de la categoría de bajo flujo (Clásica o Paradójica) y otros determinantes como la presencia/ausencia de reserva contráctil del ventrículo izquierdo. Nuestra hipótesis fue que la estenosis aórtica de bajo-flujo y bajo-gradiente, pueden ser tratada con recambio valvular aórtico con una mortalidad hospitalaria similar a aquellos con flujo normal y alto gradiente. Los objetivos del proyecto fueron el análisis de resultados hospitalarios y a medio plazo (mortalidad hospitalaria, a 1 y 5 años) así como la clase funcional y recuperación de la función ventricular, en pacientes con estenosis aórtica de bajo-flujo bajo-gradiente sometidos a recambio valvular aórtico comparado con flujo normal alto-gradiente. Nuestros resultados nos llevan a la conclusión de que el recambio valvular aórtico en pacientes con estenosis aórtica de bajo-flujo bajo-gradiente se puede lograr con baja mortalidad quirúrgica, comparable con pacientes con flujo normal y alto gradiente. A pesar de que tener una mayor mortalidad a medio-plazo, los supervivientes exhiben una excelente clase funcional y desaparición de síntomas, que apoyan la indicación quirúrgica en estos pacientes.

Importância. O uso de anticoncepcional hormonal combinado oral é associado ao aumento do risco de eventos cardiovasculares adversos desde a sua introdução na prática clínica. O mecanismo exato pelo qual podem alterar o risco ainda não foi esclarecido, sendo escassa a literatura que avalia a ação dessa classe de medicação no sistema nervoso autonômico. Objetivo. O objetivo deste estudo foi avaliar o efeito de contraceptivo contendo 20 mcg de etinilestradiol e 3 mg de drospirenona sobre a variabilidade da frequência cardíaca, da sensibilidade do barorreflexo e sobre a pressão arterial de mulheres saudáveis. Métodos. Trata-se de estudo prospectivo controlado com 69 mulheres saudáveis, divididas em dois grupos: 36 voluntárias que fizeram uso de anticoncepcional hormonal combinado oral, e 33 voluntárias que utilizaram métodos contraceptivos não-hormonais. As mulheres foram avaliadas em dois momentos, antes da introdução do método contraceptivo e seis meses após seu uso. Para a aquisição dos dados, utilizou-se o Finomoter® (FMS, Finapres Medical System, Anhem, The Netherlands), obtendo-se de forma não invasiva registros contínuos da curva da pressão arterial batimento a batimento. A análise estatística foi realizada para determinar diferenças entre os grupos e entre os momentos, sendo p < 0,05 considerado estatisticamente significativo. Resultados. No momento basal, não houve diferenças nos parâmetros demográficos, hemodinâmicos e autonômicos entre os grupos. Além disso, a comparação dos diversos parâmetros hemodinâmicos e autonômicos ao final de seis meses do método contraceptivo não evidenciou diferença tanto entre os grupos como no decorrer do tempo. Conclusão. O uso de contraceptivo contendo 20 mcg de etinilestradiol e 3 mg de drospirenona não causou alterações significativas nos parâmetros hemodinâmicos e autonômicos de mulheres saudáveis
Background. The use of combined oral contraceptives has been associated with an increased risk of adverse cardiovascular events. Whether these drugs alter cardiac autonomic nervous system control is not completely determined. Objective. The objective of this study was to evaluate the effect of a contraceptive containing 20 mcg of ethinyl estradiol and 3 mg of drospirenone on the heart rate variability, baroreflex sensitivity and blood pressure of healthy women. Methods. This is a prospective controlled trial with 69 healthy women allocated in two groups: 36 volunteers under oral combined contraceptive use and 33 volunteers under use of non-hormonal contraceptives methods. Subjects were tested before the introduction of the contraceptive method and 6 months after its use. The Finometer® (FMS, Finapres Medical System, Anhem, The Netherlands) was used for data acquisition, obtaining noninvasively continuous records of the blood pressure curve beat to beat. Statistical analysis was performed to determine differences between groups and times, with p < 0.05 considered statistically significant. Results. At baseline, there were no differences in demographic, hemodynamic and autonomic parameters between groups. A comparison of various hemodynamic and autonomic parameters after 6 months of birth control methods showed no difference between both groups as over time. Conclusion. A contraceptive containing 20 mcg of ethinyl estradiol and 3 mg of drospirenone causes no significant changes in hemodynamic and autonomic parameters of healthy women

The primary goal of my thesis research was to characterize the basis for the hypersensitive response of glycogen phosphorylase to catecholamine stimulation in primary culture diabetic cardiomyocytes. Toward this goal, I have investigated several key regulatory sites in this signaling pathway which could promote the hypersensitive activation of phosphorylase. Specifically, I investigated (1) which adrenergic receptors are involved in mediating the hypersensitive response of glycogen phosphorylase to epinephrine stimulation; (2) whether the presence of fatty acid metabolites affects phosphorylase activation; (3) whether the hypersensitive response of phosphorylase results from altered signal transduction through the β-adrenergic receptor system or from a post-receptor defect; and (4) the potential role for phosphorylase kinase in mediating the hypersensitive response of phosphorylase to catecholamine stimulation. The basis for adrenergic receptor mediation of the catecholamine-induced activation of glycogen phosphorylase was investigated in adult rat cardiomyocytes isolated from normal and alloxan-diabetic animals. Cells derived from diabetic animals exhibited a hypersensitive response to epinephrine stimulation which was apparent 3 hours after cell isolation and was further enhanced upon maintenance of the myocytes in culture for 24 hours. Normal cells initially lacked the hypersensitive response to epinephrine stimulation although upon maintenance of these cells in culture for 24 hours, the hypersensitive response was acquired in vitro. To assess alpha- and beta- adrenergic mediation of the response, normal and diabetic cardiomyocytes were incubated with propranolol, a β-receptor antagonist, prior to direct α1receptor stimulation with phenylephrine. Both normal and diabetic myocytes failed to undergo activation of phosphorylase in 3 or 24 hour cell cultures. In addition, the effects of epinephrine on phosphorylase activation were completely inhibited by propranolol whereas prazosin, an α-receptor antagonist, was unsuccessful. This data suggests that the hypersensitive response of glycogen phosphorylase in normal and diabetic cardiomyocytes is solely mediated through β-adrenergic receptor activation. Since the accumulation of various fatty acid metabolites can affect certain enzymes and signal transduction pathways within the cell, the potential effect of various fatty acid metabolites on phosphorylase activation was investigated. To determine the potential effects of fatty acid metabolites on phosphorylase activation in cultured cardiomyocytes, normal and alloxan-diabetic cells were incubated with either carnitine or palmitoylcarnitine prior to stimulation with epinephrine. Pretreatment of cardiomyocytes with or without carnitine or palmitoylcarnitine for 3 or 24 hours before epinephrine stimulation failed to alter phosphorylase activation. The addition of exogenous carnitine in the absence and presence of insulin was also unsuccessful in attenuating the hypersensitive phosphorylase activation response in 3 and 24 hour, normal and alloxan-diabetic derived cardiomyocytes. To determine if carnitine palmitoyltransferase 1 (CPT-1) activity was responsible for the hypersensitive response of phosphorylase in the diabetic myocytes, both normal and diabetic myocytes were maintained for 3 and 24 hours in the absence and presence of etomoxir, a CPT-1 inhibitor. Subsequent activation of phosphorylase by epinephrine in normal and diabetic myocytes was unaltered in the presence of etomoxir. Collectively, these data fail to support a critical role for fatty acid metabolite involvement in the hypersensitive activation of glycogen phosphorylase in acute, alloxan-diabetic cardiomyocytes. To assess potential G-protein involvement in the response, normal and diabetic-derived myocytes were incubated with either cholera or pertussis toxin prior to hormonal stimulation. Pretreatment of cardiomyocytes with cholera toxin resulted in a potentiated response to epinephrine stimulation whereas pertussis toxin did not affect the activation of this signaling pathway. To determine if the enhanced response of phosphorylase activation resulted from an alteration in adenylyl cyclase activation, the cells were challenged with forskolin. After 3 hours in primary culture, diabetic cardiomyocytes exhibited a hypersensitive response to forskolin stimulation relative to normal cells. However, after 24 hours in culture, both normal and diabetic myocytes responded identically to forskolin challenge. The present data suggest that a cholera toxin sensitive G-protein mediates the hypersensitive response of glycogen phosphorylase to catecholamine stimulation in diabetic cardiomyocytes. This response, which is present in alloxan-diabetic cells, and is induced in vitroin normal cardiomyocytes, is primarily due to a defect at a post-receptor site. To assess the role of phosphorylase kinase in the hypersensitive activation of glycogen phosphorylase in the diabetic heart, phosphorylase kinase activity was measured initially in perfused hearts (to optimize the assay parameters) and subsequently in primary culture cardiomyocytes. Results from these experiments demonstrate that the present method for measuring phosphorylase kinase activity is a reliable indicator of the enzyme's activity in the heart, although the assay conditions must be further optimized before this system can be applied to the measurement of phosphorylase kinase activity in primary cultured cardiomyocytes.

Orientador: Roseli Golfetti
Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Educação Fisica
Made available in DSpace on 2018-08-09T12:33:16Z (GMT). No. of bitstreams: 1 Costa_PriscilaStandkeda_M.pdf: 945559 bytes, checksum: 6e8fe259634c369a81db37af41658582 (MD5) Previous issue date: 2006
Resumo: O trabalho em turnos atinge de 15 a 20% da força de trabalho em países industrializados e tem sido associado com o aumento da incidência de doenças cardiovasculares. Ainda não está claro, mas a dessincronização dos ritmos circadianos do sistema nervoso autônomo cardíaco poderia explicar este fenômeno. Uma ferramenta não¿invasiva para avaliar a atividade do sistema nervoso autônomo (SNA) é análise dos componentes temporais e espectrais da variabilidade da freqüência cardíaca (VFC), calculados a partir de um registro eletrocardiográfico de 24 horas. O objetivo deste trabalho foi analisar estes componentes em 32 enfermeiras saudáveis de um hospital universitário, engajadas em turnos fixos de trabalho (idade média de 35,62 ± 6,17 anos). As voluntárias foram divididas em três grupos de acordo com o horário de trabalho: matutino (7 às 13 h), vespertino (13 ás 19h) e noturno (19 ás 7 h) e submetidas a avaliação clínica, fisioterápica e funcional cardiorespiratória. Foram levantados dados relativos ao tempo de exposição, aos hábitos pessoais (atividade física e etilismo), histórico de doenças dos progenitores e antecedentes menstruais. Além disso, foi realizado um exame clínico com aferição dos sinais vitais de repouso (freqüências cardíaca e respiratória e a pressão arterial) e com coleta de amostras de sangue para caracterização de perfil lipídico. Na avaliação fisioterápica foram mensuradas as variáveis antropométricas de peso, estatura, índice de massa corpórea (IMC), índice cintura-quadril (ICQ) e percentual de gordura corporal. A avaliação funcional cardiorespiratória constou de teste ergométrico máximo e eletrocardiografia dinâmica de 24 horas sendo que grupos de turnos diurnos (matutino e vespertino) foram monitorizados apenas num dia de trabalho e o grupo noturno em um dia de trabalho e em um dia de descanso. Nos resultados da análise da VFC e comparando os três grupos, o comportamento dos componentes simpático e vagal foi fisiológico, sem diferença estatística significativa. Porém, as voluntárias de turno noturno apresentaram maiores valores de idade, tempo de exposição, maiores valores de peso, IMC, ICQ e percentual de gordura corporal, fatores que podem interferir nos resultados obtidos tanto no teste ergométrico, quanto na eletrocardiografia dinâmica de 24 horas. Ainda assim, observou-se que os dados do grupo noturno, comparando-se dia de trabalho e de descanso, sugerem uma alteração no controle autonômico cardíaco
Abstract: In industrialized countries approximately 15 to 20% of the workforce is engaged on shift work and this is associated with an increased rate of cardiovascular diseases. It is still not clear but the alterations in circadian rhythms of the cardiac autonomic nervous system could explain this phenomenon. A non-invasive tool to evaluate autonomic nervous system activity is the emporal and spectral analysis of heart rate variability (HRV) calculated through a 24-hour electrocardiography monitoring. The objective of this study was to analyze the heart rate variations of 32 healthy nurses (ages ranging from 35, 62 ± 6, 17) engaged on fixed shift work for a university hospital. The volunteers were divided in three groups according to their working hours: morning (from 7 a.m. to 1 p.m), evening (from 1 p.m to 7 p.m.) and night (from 7 p.m. to 7 a.m.), and also submitted to clinical, physiotherapic and functional cardiorespiratory evaluations. Data relating to exposure time, personal habits (physical activity and etilism), istory of parental illnesses and monthly cycles were obtained. Additionally, a clinical examination was performed including analysis of vital signs at rest (heart and breath rate and blood pressure) and lipid profile blood tests. During the physical evaluation, anthropometric variations were measured such as weight, height, body mass index (BMI), waistto- hip ratio (WHR) and fat mass percentage. The functional cardiorespiratory evaluation included maximum ergometric and 24-h electrocardiography tests which were applied to the groups as follows: day shift-workers (morning and noon) were monitored over a period of one working day whereas the nigh shift-workers were monitored over the full working day plus the whole off-work day. Our HRV results showed physiological behaviour of sympathetic and vagal components with no significant statistical differences. However, night-shift volunteers presented older age, longer exposure time, higher weight, BMI, WHR and fat mass percentage, factors which could interfere with the HRV and ergometric test results. Therefore, we observed that the results obtained for night shift-workers, comparing work and off-work days, suggest that there are alterations in cardiac autonomic control
Mestrado
Biodinamica do Movimento Humano
Mestre em Educação Física

This project offers evidence and data to measure how progressive and sustained mobilization strategies that are implemented by nurses impact early discharge on a single stay Cardiothoracic Intensive Care Unit for patients undergoing first-time Coronary Artery Bypass Surgery (CABG) surgery.

Submitted by Mayara Moura Alves da Cruz (maya_bilac@hotmail.com) on 2019-01-29T13:55:00Z No. of bitstreams: 1 2019_01_29_Defesa completa_Mayara.pdf: 926024 bytes, checksum: 393a4084a126093e2a4b297e3c5595a0 (MD5)
Approved for entry into archive by ALESSANDRA KUBA OSHIRO ASSUNÇÃO (alessandra@fct.unesp.br) on 2019-01-29T17:20:17Z (GMT) No. of bitstreams: 1 cruz_mma_me_prud.pdf: 926024 bytes, checksum: 393a4084a126093e2a4b297e3c5595a0 (MD5)
Made available in DSpace on 2019-01-29T17:20:17Z (GMT). No. of bitstreams: 1 cruz_mma_me_prud.pdf: 926024 bytes, checksum: 393a4084a126093e2a4b297e3c5595a0 (MD5) Previous issue date: 2018-12-14
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Introdução: apesar dos benefícios da reabilitação cardiovascular (RCV) para as doenças cardiovasculares, a baixa aderência dos pacientes é uma preocupação. Ela pode estar relacionada a diversos fatores, dentre eles, à motivação e ao engajamento ao tratamento. Terapias alternativas podem melhorar motivação, engajamento e assim refletir em melhor aderência. Nesse contexto, a terapia baseada em realidade virtual (TRV) surge como uma opção para cardiopatas, contudo nesse grupo de pacientes é necessário um maior controle dos parâmetros hemodinâmicos, visto que se ultrapassados podem causar maior risco à saúde. Objetivo: investigar engajamento, motivação, barreiras e aderência frente a aplicação de TRV em cardiopatas ou pacientes com fatores de risco que participam regularmente da RCV e avaliar suas repercussões hemodinâmicas agudas. Métodos: foram recrutados participantes de um programa de RCV e alocados de forma randomizada para as intervenções RCV ou RCV+TRV. As intervenções foram realizadas por 12 semanas. Sendo o desfecho primário a avaliação o engajamento (escala de engajamento), motivação (Behavioral Regulation in Exercise Questionnaire 3), barreiras (escala de barreiras para reabilitação cardíaca) e aderência dos pacientes (frequência registrada no prontuário). O desfecho secundário foi a avaliação das repercussões hemodinâmicas agudas antes, durante e após uma sessão por meio da pressão arterial (PA), frequência cardíaca (FC), FC de reserva, frequência respiratória (f), saturação de oxigênio e percepção subjetiva de esforço (PSE). Análise estatística: foi avaliada a homogeneidade dos dados (teste de esfericidade de Mauchley) seguida da correção de Greenhouse-Geisser, quando necessário. Posteriormente foi utilizada Anova Two-Way para medidas repetidas, p<0,05. Resultados: Os pacientes de ambos os grupos apresentaram um perfil com baixas barreiras, alto engajamento e motivação e os resultados demonstram que a TRV promoveu um aumento na aderência dos pacientes que apresentavam baixa aderência à RCV convencional, porém esse aumento não se manteve após 12 semanas da interrupção do protocolo. Em relação à análise dos dados hemodinâmicos, a TRV apresentou um padrão de respostas hemodinâmicas agudas fisiológicas semelhante à RCV. Porém houve maior magnitude durante sua execução e até 5min da recuperação após a interrupção da sessão para as variáveis de FC, f e PSE (p<0,01), observados nos momentos de repouso, até um minuto, até três minutos e até cinco minutos da recuperação respectivamente em relação à TRV. Observou-se ainda que 74,07% dos pacientes que realizaram a TRV atingiram a FC de reserva em algum momento da sessão e as respostas de FC e PSE, sugerem que a TRV promoveu maior intensidade de esforço. Conclusão: A inserção da TRV ao RCV convencional aumentou a aderência após admissão de pacientes que participavam com frequência insatisfatória, o que não aconteceu com os pacientes do programa de RCV convencional, entretanto, a aderência volta a valores próximos dos iniciais após doze semanas do fim da intervenção. Porém, a TRV não estimulou a motivação e nem influenciou as barreiras e engajamento dos pacientes. Em relação aos dados hemodinâmicos, a TRV promoveu respostas agudas fisiológicas e semelhantes à RCV, mas com maior magnitude para algumas variáveis durante a sua execução e até cinco minutos da recuperação após a interrupção da sessão.
Introduction: there is a concern regarding to the low adherence of patients in cardiovascular rehabilitation (CR), despite their benefits. It may be related to several factors, among them, motivation and engagement to treatment. Alternative therapies can improve motivation, engagement reflecting in better adherence and, in this context, virtual reality based therapy (VRBT) appears as an option for cardiac patients. However, in this population, a greater control of hemodynamic parameters is necessary, once if exceed they can cause a greater risk to health. Objective: to investigate engagement, motivation, barriers and adherence through the application of VRBT in patients with cardiovascular diseases or patients with risk factors who regularly participate in CR. In addition, to evaluate their acute hemodynamic repercussions. Methods: participants of CR program were randomized to CR or CR+ VRBT. The interventions were performed for 12 weeks. The primary endpoint was engagement (User Engagement Scale), motivation (Behavioral Regulation in Exercise Questionnaire 3), barriers (Cardiac Rehabilitation Barriers Scale), and patient’s adherence (frequency recorded on the chart). The secondary endpoint was the acute hemodynamic repercussions before, during and after a session through blood pressure (BP), heart rate (HR), HR reserve, respiratory rate (rr), oxygen saturation and rate of perceived exertion (RPE). Statistical analysis: homogeneity of the data had been evaluated (Mauchley sphericity test) followed by the Greenhouse-Geisser correction, if necessary. After this, Anova Two-Way for repeated measures had been analyzed, p <0.05. Results: In both groups, patients had low barriers, high engagement and motivation. The results demonstrate that VRBT promoted an increase in adherence of patients with low adherence to conventional CR, but this increment was not maintained after 12 weeks of protocol interruption. Regarding the analysis of hemodynamic data, VRBT produce physiological acute hemodynamic responses similar to CR. However, there was a greater magnitude during its execution and until 5 minutes of recovery after session for the HR, rr and RPE (p <0.01), observed at rest, up to one, three and five minutes of recovery respectively in relation to VRBT. It was also observed that 74.07% of the patients who underwent VRBT reached HR reserve of training at some point in the session and the HR and RPE responses, suggesting VRBT promoted greater effort intensity. Conclusion: The insertion of VRBT to the conventional CR increased adherence after admission in patients who participated with unsatisfactory frequency, what did not happen with the patients in the conventional CR program, however, adherence returns to basal values after 12 weeks of the program. In addition, VRBT did not stimulated motivation and neither influence patients’ barriers and engagement. Regarding hemodynamic data, VRBT produce physiological acute hemodynamic responses similar to CR, although with greater magnitude for some variables during its execution and up to five minutes after session.
FAPESP: 2017/12254-8
CAPES: 001

This study used an in situ heart preparation to analyze the power and work of spontaneously beating hearts of four anurans (R. marina, L. catesbeianus, X. laevis, P. edulis) and three urodeles (N. maculosus, A. tigrinum, A. tridactylum) in order to elucidate the meaning of relative ventricle mass (RVM) in terms of specific cardiac performance variables. This study also tests two hypotheses: 1) the ventricles of terrestrial species (R. marina, P. edulis, A. tigrinum) of amphibians are capable of greater maximum power outputs (Pmax) compared to aquatic species (X. laevis, A. tridactylum, N. maculosus, L. catesbeianus) and, 2) the ventricles of Anuran species (R. marina, P. edulis, L. catesbeianus, X. laevis) are capable of greater maximum power output compared to aquatic species (A. tigrinum, A. tridactylum, N. maculosus). The data supported both hypotheses. RVM was significantly correlated with Pmax, stroke volume, cardiac output, afterload at Pmax, and preload at Pmax. Preload at Pmax and afterload at Pmax also correlated very closely with each other, suggesting that an increase blood volume and/or increased modulation of sympathetic tone may influence interspecific variation RVM and may have played a role in supporting higher rates of metabolism, as well as dealing with hypovolemic stresses of life on land.